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ABSTRACT 
 
Formulation of local anaesthetics in different dosage forms, including those for oral, 
parenteral, and topical application have being widely investigated. All of these 
formulations include local anaesthetics in their salt forms. The lipophilic nature of the 
bases of local anaesthetics may influence the rate of the pharmacological effect. 
There has been very little research done towards this aspect of local anaesthetics. 
 
Prilocaine base and lignocaine base possess greater lipophilicity than their salts. The 
salt forms undergo dissociation in the body. To maximise the absorption rate 
lipophilicity plays an important role. The aim of the present study is to evaluate the 
potential of using prilocaine and lignocaine individually and in combination as bases 
for parenteral formulations using cyclodextrins as complexing agents. Cyclodextrins 
are widely used as complexing agents to increase the solubility of poorly soluble 
drugs. Hydroxypropyl-β-cyclodextrin (HPβCD) was the first choice amongst the 
different cyclodextrins to be evaluated as a solubility enhancer as it does not show 
nephrotoxicity and is more bio-available compared to other cyclodextrins.  
 
Method: Prilocaine base was prepared from its salt and lignocaine base was obtained 
from Sigma Pharmaceuticals. Solubilities were examined individually and in 
combination by the phase solubility method and complex formation investigated. The 
mobile phase used was methanol:water (55:45) with phosphate buffer at pH 5.5. An 
AL type solubility isotherm was obtained for the influence of HPβCD on the 
solubilities of prilocaine and lignocaine. Complexation was investigated for both 
prilocaine and lignocaine to HPβCD by NMR.   
 
Results: The measured solubilities of prilocaine and lignocaine individually at 30% 
HPβCD from 25°C to 42°C were 1.96-7.91 moles/L and 1.69-4.55 moles/L 
respectively. The solubilities in combination were 0.91-3.68 moles/L for prilocaine 
and 1.03-8.35 moles/L for lignocaine respectively. The NMR data suggested that 
complexation involves the aromatic ring for both prilocaine and lignocaine apart from 
methene and methyl groups for prilocaine and ethyl amide and aromatic methyl 
groups for lignocaine.  
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1 INTRODUCTION 
1.1 CLASSIFICATION OF PAIN 
Happiness is what a man seeks throughout his life. Tranquility and rationality are the 
cornerstones of happiness1. Happy feelings and harmony is what every heart desires, 
but sometimes unknowingly body pain is associated with it and to produce tranquility 
and rationality we need medications like narcotics, non-steroidal anti-inflammatory 
drugs (NSAID’S) and anaesthetics. 
 
Pain is an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage. Pain can be broadly 
classified as acute pain and chronic pain. Acute pain is the normal predicted 
physiological response to an adverse chemical, thermal, or mechanical stimulus 
associated with surgery, trauma or acute illness2. Chronic pain is a state in which pain 
is persistent and the cause of the pain cannot always be removed or is difficult to treat. 
Chronic pain may be associated with a long term incurable or intractable medical 
conditions or disease. Different types of pain can be summarised as shown in  
Figure 1 below. 
 
 
 
Figure 1: Pain Classification 
 
Nociceptive pain arises from the stimulation of specific pain receptors that respond to 
heat, cold, vibration, stretch and chemical stimuli released from damaged cells. Non-
nociceptive pain arises from within the peripheral and central nervous system where 
the pain is being generated by nerve cell dysfunction3.  
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1.2 MEDICATIONS USED IN PAIN  
A variety of medications is available to control pain. They fall into the categories of 
analgesics, narcotics, and NSAID’S. These medications are generally suitable for 
giving relief of pain not associated with a surgical procedure. Pain associated with 
surgery is generally reduced by the intervention of general anaesthesia or by the use 
of local anaesthetics. Commonly used general anaesthetics are halothane, isoflurane, 
desflurane and a new compound sevoflurane with low solubility in the blood which 
expedites "wash-out' and rapid recovery from anaesthesia3. 
 
General anaesthetics are systemic in action and produce loss of consciousness, 
whereas local anaesthetics are defined as agents that cause loss of sensation with or 
without the loss of consciousness. Local anaesthetics produce anaesthesia at the site 
of application such as lignocaine, prilocaine, tetracaine/amethocaine, ropivacaine, 
bupivacaine, and mepivacaine. Local anaesthetics are used for the control of 
preoperative and postoperative pain. They fall into two categories, the aminoamides 
(amide ethers) and aminoesters (amine esters). Aminoamides include lignocaine, 
bupivacaine, mepivacaine, and prilocaine and aminoesters include procaine, 
chloroprocaine, and tetracaine. Prilocaine hydrochloride and lignocaine hydrochloride 
are the oldest and most widely used local anaesthetics. They are used as 
antiarrhythmic agents, for chronic pain relief in cases of neuralgia, and in dental 
surgeries.  
1.3 MECHANISM OF ACTION OF PRILOCAINE HYDROCHLORIDE 
AND LIGNOCAINE HYDROCHLORIDE 
A drug is often formulated into a dosage form in which it is more stable and the drug 
then undergoes transformation in the biological system to show a biological action in 
its desired form. A lipophilic drug is often more stable as its salt which is hydrophilic 
and it then dissociates in the biological system as lipophilic and hydrophilic 
components and the lipophilic component is absorbed by the cell membrane to 
produce a desired action. Local anaesthetics such as prilocaine hydrochloride 
(C13H20N2O.HCl) and lignocaine hydrochloride (C14H22N2O.HCl) show similar 
mechanisms of action in the body. 
CH3
NH C CH
CH3
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H
CH2
CH2
CH3
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Figure 2: Chemical Structure of prilocaine hydrochloride. 
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Figure 3: Chemical structure of lignocaine hydrochloride. 
 
They act by blocking the initiation and propagation of action potentials by blocking 
the Na+ channels. The activity of lignocaine hydrochloride and prilocaine 
hydrochloride is predominantly pH dependent and is increased in alkaline pH when 
the proportion of ionised molecule is low. This is because the drugs have to penetrate 
the nerve sheath and the axon membrane to reach the inner end of the Na+ channel. 
Unionised molecules of the drug show greater penetration through cell membranes 
because of the greater lipophilicity. The ionised form is not membrane permeable, 
and therefore the penetration is very poor in acidic pH. This pH dependence can be 
clinically important, since inflamed tissues are often acidic, and are thus resistant to 
local anaesthetics4. 
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The mechanism of action for lignocaine hydrochloride and prilocaine hydrochloride 
(RNH+) is well explained in Figure 4. 
 
 
Figure 4: Mechanism of action for lignocaine hydrochloride and prilocaine hydrochloride 
(RNH+). 
 
RNH+ in the tissue is in equilibrium with RN and H+. The unionised form (RN) then 
passes through the cell membrane as it possesses sufficient lipophilicity and again is 
associated with H+ to form  RNH+  which is an active form that binds to Na+ channel 
to produce its action4. Thus if lipid solubility has to be increased the drugs should 
remain in their unionised form. Thus a rapid onset of action after parenteral 
administration is postulated as the dissociation step is eliminated and alkaline pH is 
maintained, which facilitates penetration through cell membranes.  
1.4 FORMULATIONS OF LIGNOCAINE AND PRILOCAINE 
HYDROCHLORIDES 
Lignocaine has been formulated as a microemulsion. In a recent research study a 
pseudoternary phase diagram of the prepared lignocaine microemulsion with different 
surfactants and cosurfactants was reported, the diameters of droplets were determined 
and in addition viscosity, electric conductivity and refractivity. In addition its 
appearance and system type was studied by electron microscopy. A stable lignocaine 
microemulsion of the o/w type was formulated5. In another invitro study, potential of 
the application of short term iontophoresis for the topical delivery of lignocaine 
hydrochloride microemulsion was found to significantly increase the influx of the 
4 
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lignocaine in a microemulsion compared to an aqueous drug solution under the same 
iontophoresis protocol6.  
 
A trial to determine the effectiveness of a lignocaine transdermal patch for chronic 
pain was performed and proven effective for chronic pain7. Another study performed 
on only two patients, with postherpetic neuralgia suggested that application of 
lignocaine patches to the painful area helped to reduce the allodynic component of the 
pain syndrome8 i.e. occurrence of pain other than the area stimulated. There are also 
several anecdotal reports of the use of lignocaine patches in osteoarthritic knee pain 
and myofascial trigger points which are not well documented8. A 4% liposomal 
preparation of lignocaine called ELA max® is another topical preparation reported to 
be as effective as EMLA® cream - a eutectic mixture of prilocaine and lignocaine, for 
venipuncture in children, but with faster onset9,10. 
 
Prilocaine an amide local anaesthetic, is a secondary amino derivative of toluidine. It 
is somewhat less potent than lignocaine and considerably less toxic in peripheral 
tissues. Clinically it produces less vasodilation and is similar to other amide local 
anaesthetics in relative freedom from allergic reactions. Prilocaine’s primary limiting 
factor clinically is the production of methemoglobinemia, a side effect caused by its 
metabolite o-toluidine11. Prilocaine hydrochloride has been formulated mainly as a 
solution for intravenous use in regional anaesthesia12. Encapsulation of prilocaine in 
liposomes facilitated the controlled release of prilocaine increasing time duration of 
the sensory nervous blockade and constituted a good choice to replace local 
anaesthetic formulations13. Prilocaine has also been tried as a topical formulation in 
comparison with lignocaine in terms of efficacy and safety for fiberoptic 
bronchoscopy14. Pharmacokinetic studies of dermal penetration of prilocaine using a 
microemulsion formulation found eight fold increase in dermal penetration rates by 
compared to a conventional o/w type emulsion. Transdermal drug permeation from 
the microemulsion, is related to the molecular mobility of the drugs in the vehicle, 
which depends on the internal structure of the microemulsion. The study also 
demonstrated a significant decrease in the lag time and indicated a mean increase in 
dermal penetration rate of almost 2-fold that of a commercially available hydrogel15. 
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Both lignocaine and prilocaine have been formulated in combination and with other 
local anaesthetics for improved efficacy. Some of the formulations can be 
summarised as below. EMLA® cream is a successful formulation used topically in 
many surgical procedures16. It is found to be effective as a cream in both paediatric 
surgeries and in adults8, 17. 
 
A lipid depot formulation of 1:1 mixture of lignocaine and prilocaine has been 
studied in different concentrations and its use found favourable efficacy for sciatic 
nerve block as the duration of sensory sciatic block was prolonged by the lipid depot 
formulation compared to the aqueous solution18. Lignocaine with epinephrine and 
prilocaine with felypressin are the most widely used solutions by dental practitioners 
in comparison to other local anaesthetics in the UK19.  
 
Other new formulations of lignocaine based local anaesthetics include a novel 
lignocaine/tetracaine-based peel (a cream base that forms a flexible film on drying 
and comes off easily) that has recently been developed. It is applied to the skin as a 
cream and, once air dried, is removed as a flexible film. It may prove useful in 
providing adequate dermal anaesthesia for dermatologic laser surgery20.  
 
Lignocaine as such is widely formulated as parenteral and topical preparations as well 
as an oral formulation in the form of Mexiletine®. The widely formulated 
preparations of lignocaine include solutions, infusions21, microemulsions22, gels23, 
creams, sprays and patches7. 
Mexiletine®, has been used to reduce chronic pain episodes caused by 
erythromelalgia21. Lignocaine infusion has also been found to give relief of pain 
caused by erythromelalgia21. Lignocaine as a 1% and 2% solution with epinephrine is 
available as a local anaesthetic and is given to produce local anaesthesia during 
surgery, while a 5% hypertonic solution has been tried for spinal anaesthesia without 
much success24. Lignocaine as a 4% gel has been used for laser assisted anaesthesia 
prior to intravenous cannulation. Intravenous cannulation causes pain therefore, the 
procedure is assisted with topical anaesthetic agents, but the absorption of topical 
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anaesthetics is limited by the stratum corneum, the outermost layer of the epidermis.  
Laser irradiation helps remove the stratum corneum, leading to enhancement in 
uptake of topical agents like lignocaine gel23.  
1.5 DRUG SOLUBILITY 
Though there are different dosage forms such as solid, liquid, and semisolid in which 
a drug can be formulated, solutions are a desired dosage form for pharmaceuticals and 
in biological systems because drugs in solution give more rapid action compared to 
solid or semisolid dosage forms. Advantages of an oral formulation are convenience 
and ease of handling. Potential for bioavailability to large patient populations is 
achieved in solutions but faces the limitation of cost25. Lack of drug solubility is the 
main hindrance if the drug, in its original state, has to be formulated in solution or a 
parenteral form. Different methods have been tried to improve the solubility of drugs. 
 
Solubility and solubility studies thus play an important role in pharmaceuticals 
because they define the rate of dissolution of the drug. The higher the solubility of the 
drug the more rapid is its rate of solution when other factors are equal, in the absence 
of chemical reaction26. Aqueous solubility is the most desirable characteristic for both 
oral and parenteral formulations. 
 
Many factors govern the rate of drug dissolution in solution and hence the solubility. 
The  factors that are important for the discussion are the nature of the drug substance, 
its hydrophobicity, its shape, its surface area, its state of ionisation, the influence of 
pH, and drug pKa26.  
The influence of the nature of the drug substance can be explained with the example 
of novobiocin an aminocoumarin antibiotic used against Staphylococcus species. The 
acid salt of novobiocin is absorbed, but its ionised state as the monosodium salt 
shows an increase in solubility by about 300 times. The solution of ionised 
novobiocin was found to be unstable. Knowledge about its shape and structure shed 
some light on how to obtain a stable and more soluble form, thus the amorphous form 
of novobiocin was found to give higher solubility than its crystalline form or its 
sodium salt26. 
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The ionisation state of a drug also plays an important role and is governed by two 
major factors. A) The entropy of mixing which favours complete miscibility of all 
components. B) The difference between the sum of the drug-drug (DD) and water-
water (WW) interactions on the one hand and the drug-water (DW) interactions on 
the other. This difference is related to the activity coefficient of the drug in water γw 
by 
 
RT ln γw = DD + WW – 2DW                                                    Eq (1) 
If, 
DD + WW -2DW > 0                                                                  Eq   (2) 
 
as is the case with non electrolytes in water, there will be less than complete mixing 
and the drug will have a finite solubility in water. The greater the difference between 
(the adhesive) and (cohesive) interactions, the lower the solubility will be.  
 
Mathematically, the observed solubility of a solute Xw is given by the ideal solubility 
and the activity coefficient as  
 
log Xw = log Xi – log γw                                                                                            Eq   (3) 
 
Where Xw = observed solubility of a solute in water. 
            Xi = ideal solubility of a solute in water. 
 
            
 
 
Both crystalline structure effects as reflected by Xi and solution interactions as 
reflected by γw can contribute to the insolubility of a solute and both these factors can 
be modified as a means of solubilising the drug27. 
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Many drugs are either weak organic acids or weak organic bases or their salts and the 
degree to which these drugs would ionise in solution is dependent upon the pH. pH 
thus is one of the primary influential properties that has an effect on the solubility of 
most drugs that contain ionisable groups. The degree of ionisation is one of the most 
important parameters considered for improving the solubility of acidic and basic 
drugs. This can be illustrated by the example of tetracycline hydrochloride solution. 
The hydrochloride in tetracycline lowers the pH of tetracycline hydrochloride 
increasing its solubility. Similarly, erythromycin is labile at pH 4 and hence unstable 
in the stomach contents. Erythromycin is an active form which shows antimicrobial 
action. Thus conversion of erythromycin to erythromycin stearate makes it less 
soluble in the stomach and is not as susceptible to degradation and dissociates in the 
intestine yielding the free base. Thus, making erythromycin less soluble in the 
stomach shows enhanced activity26. 
 
To improve the solubility of certain drugs pH control and inclusion complex 
formation methods can be used as solubilisation techniques. An example of this is 
naringenin, a weakly acidic compound with low water solubility. A study evaluated 
that the combined use of ionization and complexation increased the solubility of the 
unionized and ionized naringenin. This study provides evidence of the role of pH, pKa 
and complexation in increasing the total aqueous solubility. The study was carried out 
at pH 4 and 8 with inclusion complex formation with parent beta cyclodextrin (βCD), 
and its derivatives of 2-hydroxypropyl-βCD (HPβCD) and methyl βCD. An AL 
profile obtained suggested that naringenin, both in the uncharged and charged state 
formed soluble complexes in a 1:1 ratio, to different extents. The study also proposed 
that the affinity of the unionized naringenin for the hydrophobic cavity of 
cyclodextrin is higher than that of the ionized form, due to the more hydrophilic 
character of this form28. 
 
In another study performed on thiazolobenzimidazole similar results were obtained. 
Thiazolobenzimidazole is an experimental drug for the treatment of AIDS and 
exhibits low water solubility (11µg/mL) and is almost impossible to administer in an 
injectable solution at a target concentration of 10 mg/mL. Thiazolobenzimidazole has 
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a single ionisable functional group which exhibits an increase in solubility with 
decreasing pH consistent with a pKa of 3.55 and the maximum solubility attainable 
by pH adjustment was only 0.4mg/mL (at pH 2). The inclusion complex of 
thiazolobenzimidazole in either its neutral or protonated form with HPβCD was found 
to improve solubility by forming 1:1 complexes. The equilibrium constants obtained 
were at 81 and 1033 M-1 respectively, this giving a 3 fold greater solubility. Although 
the formation of a protonated complex was less favoured in comparison to the neutral 
complex, contribution of this species to the overall solubility of 
thiazolobenzimidazole predominated at low pH. Thus, using a combined approach of 
pH enhancement and complexation with HPβCD, gave a solubility enhancement of 
three orders of magnitude29. 
 
Factors such as polymorphism or nonsolvated crystals and anhydrate solutes also 
affect drug solubility or dissolution and are related to drug absorption. In a recent 
study the general trends of solubility ratios of polymorphs for 55 compounds (81 
solubility ratios due to existence of multiple forms for some compounds) and the 
ratios of anhydrate/hydrate for 17 compounds (924 ratios due to existence of multiple 
forms) were evaluated. The study for polymorphs was based on both aqueous and 
nonaqueous solubility data because polymorph solubility ratio is independent of the 
solvent used, whereas for the anhydrate/hydrate solubility ratios, only aqueous 
solubility ratios were used. The study was carried out in the temperature range of 20-
40ºC. The study revealed that polymorph solubility ratio and anhydrate/hydrate 
solubility ratios were typically less than 2, but the anhydrate/hydrate solubility ratios 
appeared to be more spread and higher than the typical ratio for nonsolvated 
polymorphs30.  
 
Like polymorphs the amorphous form of pharmacologically active materials has also 
received considerable attention because it represents the most energetic solid state of 
a material and thus provides the biggest advantage in terms of solubility and 
bioavailability. For polymorphs the improved solubility can be estimated from the 
knowledge of different thermodynamic properties of the different forms such as the 
melting point, heat of fusion, and heat capacity of each form. The measurement and 
11 
 
 
estimation of the solubility and bioavailability improvements of the amorphous form 
of a drug present a significant challenge because of the non equilibrium nature of the 
amorphous state. The two major limitations that affect correct measurements are the 
difficulty involving the accurate characterisation of the thermodynamic properties and 
its tendency to rapidly revert to the crystalline state upon exposure to small quantities 
of solvents31.  
1.5.1 SOLUBILITY AND PARENTERAL FORMULATIONS 
 
Solubility plays an important role when the drug is to be formulated for parenteral 
purposes. Although insoluble drugs can be given in oral formulations in the form of 
suspensions or emulsions, parenteral formulations are preferred to use solutions. 
Parenteral administration of sparingly soluble substances, especially by the 
intravenous (IV) route, is a major challenge in the pharmaceutical industry, and 
several techniques have been used to increase the solubility of a drug. Additives, such 
as salts, cosolvents, surfactants, and complexing agents are all means to improve the 
solubility of an insoluble drug to an extent that can be predictable26.  
 
Converting a drug to its salt form is one way of improving the solubility, but not all 
drugs show biological activity or desired action in their salt form, and thus other 
approaches for increasing the solubility include cosolvents, surfactants, complexation 
ligands, and lipids32. Solvent modification is achieved by use of cosolvents such as 
ethanol, propylene glycol, polyethylene glycol 400 and glycofurol. Surfactants used 
to improve solubility fall into the categories of ionic and non ionic surfactants in 
microemulsions and self-emulsifying drug delivery systems (SEDDS). Complexation 
techniques include modification of solubility with complexing ligands like 
cyclodextrin33. A new technique of forming an isotropic system with mono and 
diglyceride agents such as Capmul® is also suggested as a method to improve the 
solubility of an insoluble drug for parenteral formulation.  
 
1.6 SOLUBILITY IMPROVEMENT BY THE COSOLVENCY METHOD 
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The most widely used method in the pharmaceutical sector so far for solubilisation of 
an insoluble drug is cosolvency. It is a technique, in which the drug is more soluble in 
a mixture of solvents than in one solvent alone, cosolvency has being employed for 
wide range of dosage forms for the improvement of solubility34.  
 
Cosolvents reduce the hydrogen bond density of aqueous systems that reduce the 
cohesive force interactions of water and make water less effective in squeezing out 
nonpolar solutes from the solution. The combination of the hydrogen group makes the 
cosolvent part polar and part nonpolar thus reducing surface tension, dielectric 
constant, and solubility parameters which result in increased solubility of nonpolar 
solutes34. Thus cosolvents act by reducing the polarity by interfering with water-water 
hydrogen bonds34. 
 
Cosolvency has been utilised in different formulations including solids and liquids. 
For example various concentrations (5-40%) of the solid binary systems with 
polyethylene glycol 6000 were employed to increase solubility and dissolution of 
meloxicam35. Cosolvency techniques have also found use in spray freezing of liquid 
like in Danazol with polyvinyl alcohol, poloxamer 407, and polyvinylpyrrolidone K-
15 in a micronised powder formulation36.  
 
Though cosolvency has been highly utilised in the design of many different 
formulations, it has found its main use in parenteral dosage forms because of the 
irritating effects of most surfactants and the low toxicity of many cosolvents, and 
because of the relatively greater ability of cosolvents to solubilise nonpolar drugs. 
The most frequently used low toxicity cosolvents for parenteral use are propylene 
glycol, ethanol, glycerin, and polyethylene glycol27. For example drugs like 
ketoprofen for aqueous injection have increased the aqueous solubility by using 
hydrotropes and the cosolvency method37.  
 
The solubility of Septrin® infusion has been improved by the cosolvency method. 
Septrin® is an admixture of a poorly soluble weakly acidic drug sulphamethaoxazole 
and the weakly basic drug trimethoprim. When mixed together the admixture is 
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incompatible and precipitates. Addition of 40% propylene glycol allows both 
substances to coexist in solution form26. 
 
For parenteral formulations such as an intravenous infusion of biphenyl-dimethyl 
dicarboxylate (BDD) concentrate, cosolvency proved to be the method of choice.  
BDD is a synthetic analogue of schizandrin C, one of the lignoid-type components 
isolated from Fructus schizandrae, and has been widely prescribed for improvement 
of liver function and symptoms of patients with liver disease. Its oral preparations 
have limited bioavailability due to its extremely low solubility in water. A study using 
a ternary solvent system of N,N-dimethylacetamide (DMA)/alcohol/water and 
Cremophor EL/DMA/alcohol were found to effectively improve the solubility of 
BDD in these cosolvents and surfactants, and the results showed that the cosolvent 
systems were effective for solubilizing BDD up to the concentration that might be 
employed for preparation of parenteral dosage forms38. 
 
1.6.1 COSOLVENTS AND ADDED MATERIALS 
Solubilisation of a drug with cosolvency alone can be a difficult task, due to the 
ability of the drug to precipitate upon dilution in the blood stream. The addition of 
surfactants or complexing agents can successfully overcome this problem. For 
example the solubility of two poorly soluble drugs indomethacin and phenytoin was 
studied using a mixture of DMA and dimethylsulfoxide (DMSO) and Gelucire® 44/14 
as a surface active agent. Cosolvents DMA and DMSO affected the micellar 
morphology. DMA helped form large structures by being entrapped in the 
hydrophobic region of the micelles and DMSO reduced the interfacial layer. It was 
found that Gelucire® as a surfactant did not significantly improve the solubility 
profile of indomethacin and phenytoin34. 
 
In another study flavopiridol [5,7-dihydroxy-8-(4-N-methyl-2-hydroxypyridyl)-6' -
chloroflavone hydrochloride] a flavanoid with weak electrolyte properties and an 
intrinsic aqueous solubility of 0.024 mg/mL was combined with a buffer and 
cyclodextrin and a buffer  and cosolvent. It was known that cosolvency, complexation, 
or pH control alone cannot produce an acceptable 10 mg/mL formulation that will not 
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precipitate when diluted in the blood stream. Therefore, a combination study was 
undertaken to analyse if an acceptable 10 mg/mL formulation could be produced. 
This study found that flavopiridol shows good stability for at least one year in 30% 
HPβCD/0.1 M citrate buffer (pH 4.52) and does not precipitate for at least one hour 
upon dilution with Sorensen's phosphate buffer pH 7.439. 
 
Yet another study has combined the effects of cosolvency and cyclodextrin for a 
nonpolar drug. Fluasterone, was studied by employing a mathematical model. 
Fluasterone is a structural analogue of dehydroepiandrosterone used for cancer 
treatment. This study determined the total drug solubility of fluasterone by the 
summation of three drug species present in the solution: free drug [D], drug-ligand 
binary complex [DL], and drug-ligand-cosolvent ternary complex [DLC]. The model 
established the dependencies of the three species. The intrinsic drug solubility, [D(u)], 
the cosolvent solubilizing power, δ, the binary and ternary intrinsic complexation 
constants, K(b)(int) and K(t)(int), and the cosolvent destabilizing powers for the 
binary and the ternary complexes, rho(b) and rho(t). The model explained the decline 
in drug solubility produced by low cosolvent concentrations as well as the increased 
solubility produced by high cosolvent concentrations that were observed at all 
cyclodextrin concentrations40. 
1.6.2 THEORIES FOR COSOLVENCY 
Methods to determine cosolvency fall into log-linear models and non log-linear 
models. The log-linear model is the simplest proposed model, which suggests that the 
solute is not altered by the solvent, the crystal structure of the solute remains 
unchanged, and the solvent does not dissolve in the solute and remains pure. The 
model also suggests that the composition of a mixed solvent is a linear combination 
of its components and that the free energy of mixing a solute with a mixed solvent, 
Gmix, is a linear combination of its free energy of mixing with the component solvents.  
 
                                            ∆ Gmix = fw ∆Gw + fc ∆Gc                                  Eq (4) 
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Where ∆Gw is pure water, ∆Gc is pure solvent, and fw and fc are the volume fractions 
of water and cosolvent in the mixture, respectively. Replacing the free energy terms 
with their corresponding solubilities gives:  
 
                                           log Smix = fw logGw + fc logGc                           Eq (5) 
 
where S is the molar solubility of the solute. Solubilities of methyl, propyl, and butyl 
esters of p-hydroxy- and p-aminobenzoates have been determined in propylene 
glycol:water mixtures and positive deviations were observed at high volume fractions 
and negative deviations were observed at low volume fractions37. Log-linear 
cosolvency models have been studied for solubilisation in the most common solvents 
such as propylene glycol, ethanol, polyethylene glycol 400, and glycerin41. 
 
Other linear models used to determine cosolvency are an extended Hildebrand 
solubility approach, excess free energy equations, combined nearly ideal binary 
solvent/Redlich-Kister equation and Margule equations. These can be converted into 
a general single model which expresses the logarithm of mole fraction solubility of a 
solute as a power series of volume fraction of the cosolvent. The non linear models 
include the mixture response surface methods, two step solvation model and modified 
Wilson model which can be converted to a nonlinear general form. It has also been 
shown that the general single model and a non-linear general model are 
mathematically identical42.  
1.7 SOLUBILISATION OF DRUGS USING MICROEMULSIONS 
Microemulsions, are a branch of emulsion technology and a concept that was 
introduced in the 1940s by Hoar and Schulman when they successfully generated a 
single phase dispersion by using a milky emulsion with hexanol43. Though the 
concept is old it was found that these formulations attracted particular attention in 
regards to improved solubility. For example, an improved solubility was obtained for 
transdermal delivery of poorly water-soluble Vinca alkaloid derivative, vinpocetine 
by use of oleic acid, Labrasol® (C8 and C10 polyglycolysed glycerides), Transcutol 
P®, and double-distilled water. Vinpocetin showed about 3160-fold increased 
16 
 
 
solubility compared to that in water and the apparent permeation rate across excised 
rat skin was improved44. 
 
In yet another study, acyclovir, a poorly soluble drug, displayed higher solubility in 
microemulsion formulations using Labrafac® (10%), Labrasol® (32%), Plurol 
Oleique® (8%), and water (50%). The in vitro intraduodenal diffusion and in vivo 
study revealed an increase of bioavailability by 12.78 times after oral administration 
of the microemulsion formulation as compared with the commercially available 
tablets45. 
 
Apart from improving the solubility of many known drugs, microemulsions also act 
as drug delivery vehicles by incorporating a wide range of drug molecules. 
Microemulsions have been shown to be able to protect labile drugs, control drug 
release, increase bioavailability and reduce patient variability46. Furthermore, it is 
also possible to formulate microemulsions for most of the routes suitable for 
administration such as oral47 ocular, pulmonary, topical48 and intravenous 46,49.  
1.7.1 SURFACTANTS FOR MICROEMULSIONS 
Surfactants/or surfactant mixtures/and or cosurfactants in microemulsions play an 
important role in improving the solubility of drugs formulated as microemulsions, but 
pose the greatest challenge in the design of a thermodynamically stable 
microemulsion formulations47. The surfactant/mixture of surfactant/and/or 
cosurfactant form a microstructure at the interface of a two phase system, forming a 
one phase isotropic system. The surfactant can be non-ionic like polyoxyethylene 
surfactants eg Brij 35 or sugar esters like sorbitan monooleate (Span 80)50, cationic, 
or anionic like alkyltrimetylammonium bromide50 and sodium dodecyl sulphate, or 
zwitterionic such as phospholipids like lecithin (phosphatidylcholine) commercially 
available from soybean and eggs. Lecithin is very popular because it exhibits 
excellent biocompatibility46. Combinations of ionic and non-ionic surfactants are also 
found to be effective at increasing the extent of the microemulsion region.  
 
Dependent on the polar head and a nonpolar tail and the self association of a 
surfactant molecule, a number of different structures are formed giving an optically 
isotropic microemulsion phase. This is represented in Figure 5, which shows different 
phases that are formed by self-association of the surfactant46.  
 
 
Figure 5: Schematic representation of the most commonly encountered self-association 
structures in water, oil or a combination thereof. 
 
1.7.2 TYPES OF MICROEMULSIONS 
 
Three types of microemulsions that are formed are oil in water, (o/w emulsion), 
where the volume of the oil fraction is less, or water in oil emulsion, (w/o emulsion), 
where the volume of the water is less and a bi-continuous microemulsion where 
amounts of water and oil are similar. 
1.7.3 PHASE BEHAVIOUR OF MICROEMULSIONS IN IMPROVING 
SOLUBILITY 
The improvement or enhancement of solubility using microemulsions and the 
surfactant properties can well be explained by the ternary phase behaviour diagram. 
The phase behaviour of simple microemulsion systems is represented by oil, water 
and surfactant. In the case of microemulsions for pharmaceutical applications, the 
microemulsion will contain additional components such as a cosurfactant and/or drug. 
In this case pseudo-ternary phase diagrams are used, where a corner will typically 
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represent a binary mixture of two components such as surfactant/cosurfactant, 
water/drug or oil/drug46. The typical hypothetical pseudo-ternary phase diagram is 
shown in Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: A hypothetical pseudo-ternary phase diagram of an oil/surfactant/water system with 
emphasis on microemulsion and emulsion phases. Within the phase diagram, existences fields are 
shown where conventional micelles, reverse micelles or water-in-oil (w/o) microemulsions and oil 
in water o/w microemulsions are formed. 
 
1.7.4 PROBLEMS ENCOUNTERED WITH MICROEMULSIONS 
 
Microemulsions have been employed to increase the solubility of many drugs that are 
practically insoluble in water, along with incorporation of proteins for oral, parenteral, 
as well as percutaneous/transdermal use. 
 
Although, microemulsions are considered to be thermodynamically stable systems 
with low viscosity, using the correct surfactant and/or surfactant mixture and/or 
cosurfactant in a correct concentration poses the greatest challenge in the design of a 
thermodynamically stable microemulsion formulation47. To overcome this problem 
much research has been reported. A recent study has shown that microemulsions 
formulated using medium chain triglycerides as a nonpolar component and lecithin 
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and short chain alcohol/C3-C4 as a surfactant improves the stability of 
microemulsions47. Another study suggested strategies to choose 
surfactants/cosurfactants for the formation of a stable and dilutable microemulsion47. 
 
Microemulsions have been used mainly in topical, oral, ocular, pulmonary, and 
parenteral formulations. In topical formulations, microemulsions are mainly 
employed to enhance the percutaneous, dermal, or epidermal absorption of the drug. 
For example o/w and w/o microemulsions based on oleic acid as oil phase and 
mixtures of Labrasol® and Plurol Oleique CC 497® as surfactant were employed in 
the delivery of prostaglandin E151. 
 
Another study evaluated absorption of oral nanocapsules of insulin dispersed in a 
microemulsion for intragastric administration to diabetic rats using poly (iso-butyl 
cyanoacrylate) (PBCA) for nanoencapsulation. The microemulsion consisted of a 
mixture of medium-chain mono-, di- and tri-glycerides as the oil component, 
polysorbate 80 and sorbitan mono-oleate as surfactants and an aqueous solution of 
insulin. The intragastric administration of insulin-loaded nanocapsules dispersed in 
the biocompatible microemulsion resulted in a significantly greater reduction in blood 
glucose levels of diabetic rats than an aqueous insulin solution or insulin formulated 
in the same microemulsion. This study demonstrated that the formulation of peptides 
within PBCA nanocapsules that are administered dispersed in a microemulsion can 
facilitate the oral absorption of encapsulated peptides52.  
 
Microemulsions can be employed for IV use47, however, IV administration imposes 
rigorous demands on the non-toxicity of the formulations33. Aqueous parenteral 
formulations containing propofol using o/w microemulsion systems were developed 
in a recent study. Propofol is an oily liquid and therefore was used as the oil phase 
and its content fixed to 1%, w/w. Pseudoternary phase diagrams reflected the 
concentration range of surfactant and cosurfactant and the optimum ratio between 
them for microemulsion formation. The suitability of the microemulsion as a 
parenteral formulation was evaluated from the stability and haemolysis tests. Among 
the surfactants and cosurfactants screened, a mixture of Solutol HS 15-ethyl alcohol 
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(5/1) showed the largest o/w microemulsion region in the phase diagram. It was found 
that 1% (w/w) of propofol was solubilised with 8% (w/w) of Solutol HS® 15-ethyl 
alcohol (5/1) to obtain an average droplet size (150 nm). The content of propofol in 
the systems was not significantly changed at 40°C for 8 weeks. The haemolysis test 
also showed that this formulation was non-toxic to red blood cells. Thus, this study 
proposed that propofol can successfully be solubilised with an o/w microemulsion 
system53. 
 
In another study an attempt was made to develop a poorly water-soluble lipophilic 
drug ibuprofen eugenol ester using a phospholipid-based microemulsion. Ibuprofen 
eugenol ester (IEE), a highly lipophilic compound, was synthesized from ibuprofen 
and eugenol. A micromulsion system was formulated consisting of Miglyol 812®, 
soybean lecithin (SbL) and poly (ethylene glycol), (660)-12-hydroxystearate (Solutol 
HS-15®), and PEG 400 and ethanol as oil phase, along with surfactants and 
cosurfactants, to form a stable parenteral microemulsion. The ibuprofen blood 
concentration after intravenous administration of the microemulsion was determined 
and compared with that of an ibuprofen solution. The solubility of IEE obtained in 
this form was about 21,000 times higher than that in water. It was concluded that the 
microemulsion system might be a promising intravenous dosage form of poorly 
water-soluble lipophilic drugs54. 
 
The solubility of flurbiprofen, a poorly water-soluble drug, was improved by 
formulating it in an oil-in-water (o/w) microemulsion suitable for parenteral 
administration. Varying ratios of oil to surfactant were prepared with ethyl oleate, 
Tween 20 and an isotonic solution. The effect of the particle size of the 
microemulsion and solubility of flurbiprofen in the microemulsion were studied. The 
mean droplet diameter of microemulsions containing less than 1% (w/w) of 
flurbiprofen was below 100 nm. However, the mean droplet diameters tended to 
increase at room temperature. When the different systems were compared it was 
found that the pharmacokinetic parameters of flurbiprofen after intravenous 
administration of a flurbiprofen-loaded microemulsion to rats were not significantly 
different from those of flurbiprofen in phosphate-buffered saline solution. The 
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maximum solubility of flurbiprofen in the microemulsion system was found to be 10 
mg/ml. It was concluded that microemulsions of flurbiprofen prepared with ethyl 
oleate and Tween 20 can be used as a parenteral drug carrier for this and other poorly 
water-soluble drugs, provided that physical stability can be properly addressed55,52.  
1.8 SELF-EMULSIFYING DRUG DELIVERY SYSTEM (SEDDS) 
This method is a new approach to emulsions for improving the solubility of 
incorporated drugs. Self-emulsifying drug delivery systems (SEDDS) are closely 
related to but a different branch of emulsion systems. The two new approaches that 
are applied to make the insoluble drugs soluble by this system are self-
microemulsifying drug delivery system (SMEDDS) and self-nanoemulsifying drug 
delivery system (SNEDDS). 
 
SMEDDS typically comprises a mixture of surfactant, oil and drug (known as the 
concentrate) which when introduced into the body is rapidly dispersed to form 
droplets of approximately the same size range as those observed in microemulsion 
systems. Once dispersed such systems would be expected to behave in vivo in much 
the same way as oil-in-water (o/w) microemulsions.  
 
Self-nanoemulsifing systems (SNEDDS) are isotropic mixtures of oil, surfactants, 
and cosurfactants along with the drug. When these systems come in contact with 
gastrointestinal fluids, they disperse as very fine droplets in the nanometer size range. 
The droplet size, turbidity, and drug release characteristics depend on formulation 
variables, such as the nature and concentrations of the oil, surfactant, or cosurfactant56. 
 
SEDDS systems are mainly used to improve the solubility of water insoluble drugs 
for oral absorption. These systems have not been employed in parenteral formulations. 
For example, a recent in vitro study of SEDDS and SMEDDS systems using 
carvedilol, a poorly water soluble drug, showed an increase in the solubility, 
dissolution rate, and, ultimately, oral bioavailability. SEDDS and SMEDDS showed 
that the dissolution rate for carvedilol was more than double when compared with that 
from tablets. Also the SEDDS formulation significantly improved the oral 
bioavailability of carvedilol by 413% when compared with commercially available 
tablets57. 
1.9 SOLUBILISATION OF DRUGS BY USE OF COMPLEXING AGENTS 
Complexation is defined as the reversible association of m molecules of a substrate S 
with n molecules of a ligand species L to form a new species SmLn27. This can be 
shown in the following Equations (6 and 7) 
 
SmLnnLmS nKm⎯⎯ →←+ :          
                                                                                                                       Eq (6) 
The equilibrium constant Km:n for the interaction may be defined as  
[ ]
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                                                                        Eq (7) 
There are different types of complexes that are formed and these can be defined in 
terms of association or complexation constants and equilibria27. 
 
Types of complex Examples 
Coordination Cis-Dichlorodiamineplatinum (II) 
Chelates Calcium EDTA 
Metal-olefin Ferrocene 
Inclusion Digitonin-cholesterol 
Molecular complexes Phenol-PEG; benzoic acid-caffeine 
 
Cyclodextrins(CD’s) are heterogeneous, amorphous, hygroscopic substances, 
produced in large quantities by a hydrolytic process and obtained as the primary 
product from the splitting of the glycosidic linkage with one molecule of water58. 
 
CD’s have a hydrophilic outer surface and a lipophilic central cavity. CD molecules 
are relatively large with a number of hydrogen donors and acceptors and, thus, in 
general they do not permeate lipophilic membranes. In the pharmaceutical industry 
CD’s have mainly been used as complexing agents to increase aqueous solubility of 
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poorly soluble drugs, and to increase their bioavailability and stability. Studies in both 
humans and animals have shown that CD’s can be used to improve drug delivery 
from almost any type of drug formulation59. 
The three major CD’s are crystalline, homogeneous, non-hygroscopic substances, 
which are of a torus-like macro ring shape, built up from glucopyranose units.  α- CD 
or cyclomaltohexose comprises 6 glucopyranose units. The β-CD or 
cyclomaltoheptose comprises 7 glucopyranose units. The γ- CD or cyclooctaamylose 
comprises of 8 such units58.  
1.9.1 CYCLODEXTRINS AND SOLUBILISATION OF DRUGS 
To determine whether CD’s are the right choice as solubilisation enhancers for poorly 
water soluble drug the CD utility number is used. The solubilisation of a poorly 
soluble drug can be explained as follows: 
 
The fundamental property that describes the strength of interaction between a drug 
and a CD is the binding constant (or stability constant) K, which is related to the 
thermodynamic property ∆G0, standard free energy change during complexation. 
                                                                                            Eq (8) 
 
The total aqueous solubility of drug (St, mol/L) in the presence of a given total CD 
concentration (CCD, mol/L) is described by the following equation:  
 
                                                                             Eq (9) 
 
where S0 is the aqueous solubility of the drug in the absence of CDs. For any 
formulation where complete drug solubilization by CD complexation is required, the 
practical utility of CDs as efficient solubilizers depends on (1) the binding constant, K, 
(2) the drug intrinsic solubility, S0, (3) the dose of the drug, and (4) the maximum 
workable amount of CD. Thus a new dimensionless number, named the CD utility 
number (UCD) has been introduced to assess the feasibility of the use of CDs in 
dosage forms depending on the above mentioned factors. 
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Let the dose of drug and total amount of workable CD be Dt (mol) and CDt (mol), 
respectively. Also, let V (L) be the volume available for the formulation to dissolve. 
This may be the volume of injectable solution or the volume available in the GI tract 
for an immediate release oral dosage form to dissolve or volume inside a coated 
modified release dosage form (e.g., osmotic pump tablet). For the entire dose of drug 
to be in solution  
                                                                                                          Eq (10) 
 
Substituting 9 into 10,  
 
                                                                                Eq (11) 
 
Upon further rearrangement,  
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The first term, SoV/Dt, is the inverse of the dose number, a dimensionless number that 
has been used to classify drugs as poorly and highly water soluble. It is generally less 
than one for poorly soluble drugs and therefore it is reasonable to assume that the first 
term is negligible. The second term of eq. 12 can be defined as the CD utility number, 
UCD and is expressed as:  
 
                                             Eq (13) 
 
where mD and mCD are the drug dose and workable amount of CD in mg, respectively, 
and MWD and MWCD are molecular weights of D and CD, respectively. When the 
dimensionless number, UCD is greater than or equal to one, solubilization is 
adequately provided by complexation by CDs. When the dimensionless number is 
less than one, the complexation alone is not enough for complete solubilization. The 
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workable amount of CD, mCD can also be fixed based on the dosage form type, 
weight or volume limit (tablet size), tonicity of the solution (parenteral or ophthalmic), 
toxicity, cost etc. For the application of Eq. 13 in determining the utility of CD for a 
specific drug formulation, only the value of the binding constant, K needs to be 
determined60. 
1.9.2 ASSOCIATION CONSTANT AND CYCLODEXTRINS 
The association constant (K) is a constant that is determined by the association 
between the drug molecule (D) and the cyclodextrin molecule (CD). One molecule of 
(D) may be associated with one molecule of (CD), or two molecules of (D) may be 
associated with one molecule of (CD), or one molecule of (D) may be associated with 
two molecules of (CD). This can be explained by Figure 7 showing phase diagrams.  
 
 
 
Figure 7: Schematic representation of the A-type phase diagrams 
 
The type A phase diagram represents systems in which the complex formed is soluble 
and does not precipitate regardless of the amount of ligand. Depending upon the type 
of association between the (D) and the (CD) three types of variations are seen in the 
phase diagram. The AL model represents the association constant of K1:1 which 
means that one molecule of (D) forms a complex with one molecule of (CD) and a 
linear relationship exhibits. This can be explained by the following equation where m 
and n=1. 
 
    D + CD        D - CD                                                                        Eq (14) 
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 Type AP system represents where one molecule of (D) forms a complex with two 
molecules of (CD) and a positive deviation from linearity is obtained. This is 
expressed as in the equation given below. 
 
      D + 2CD   DCD2                                                                              Eq (15) 
The type AN exhibits a negative deviation which represents a decreasing dependence 
on CD added at higher CD concentration. This type is the least frequently 
encountered system27.  
 
     2D + CD   D2CD                                                                           Eq (16)                               
 
Generally the most common stoichiometry of drug/CD complexes is 1:1, and is often 
studied by the phase-solubility method. However, in recent years it has becoming 
increasingly clear that solubilizing effects of CD’s are frequently due to the formation 
of multiple inclusion and non-inclusion complexes. A study of the aqueous solubility 
of 38 different drugs in aqueous solution, aqueous buffer solutions and aqueous 
cyclodextrin solutions, found that the apparent stability constant (K1:1) of the 1:1 
drug/cyclodextrin complexes calculated by the phase-solubility method shows strong 
negative deviation from the intercept solubility (Sint) and the intrinsic solubility (S0) 
for poorly soluble drugs with aqueous solubility <0.1mM (or approximately 
0.03mg/mL). In the case of drugs with intrinsic solubility (S0) values greater than 
1mM the (Sint) nearly equals the (S0). (S0) is in general much larger for poorly soluble 
than the intercept of the phase-solubility diagram (Sint) resulting in non-linearity of 
otherwise linear (AL-type) phase-solubility diagram. This leads to erroneous K1:1 
values61.  
 
It is not clear why the intercept of the phase-solubility diagram is below S0 but it 
could be due to the non-ideality of water as a solvent. Usually we treat solvents as 
homogenous and ideal but somewhat random structure of solvent molecules that are 
more or less independent of each other. In recent years it has become increasingly 
clear that water is a highly structured solvent with many unique physicochemical 
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properties that have yet to be explained at a molecular level. For example, the 
molecular structure of water allows the water molecules to form a cage around non-
polar solutes without sacrificing much of their hydrogen bonding capacity. Structured 
water can close on the solute like elastic net trapping one or more solute molecules. 
This physicochemical property of water can be responsible for some of the solubility 
irregularities observed in pure aqueous solutions61. 
 
To avoid this discrepancy in solubilities a more accurate method for determination of 
the solubilizing efficiency of CD is to determine their complexation efficiency (CE), 
i.e. the concentration ratio between CD in a complex and free CD. CE is calculated 
from the slope of the phase-solubility diagrams, it is independent of both S0 and Sint, 
and more reliable when the influences of different pharmaceutical excipients on the 
solubilization are being investigated61. 
1.9.3 PHYSICOCHEMICAL ASPECTS OF DRUG AND COMPLEXES 
Complexes form in aqueous solutions as the result of the additive effects of a variety 
of intermolecular interactions. The forces which act are London dispersion, dipolar 
(including hydrogen bonding), ionic, and hydrophobic forces. A single type of 
bonding is not dominant in a solution between the drug and complexing agent. 
However, most small molecules that form complexes exhibit molecular features by 
forming intermolecular hydrogen bonding which results in a non-planar configuration. 
It has been strongly suggested that planar configuration stack together and is 
generally associated with aromatic moieties. However, this is not the case with most 
of the drugs of pharmaceutical interest as they are non planar and/or non-aromatic.  
For a drug to form a complex with a suitable agent both the drug and the complexing 
agent should exhibit similar interaction chemically. Mostly this is exhibited by the 
formation of hydrogen bonding between a drug and a complexing agent27. 
1.9.4 FACTORS INFLUENCING INCLUSION COMPLEX FORMATION 
The type of CD can influence the formation as well as the usefulness of drug/CD 
complexes. For complexation, the cavity size of the CD should be suitable to 
accommodate a drug molecule of a particular size62. Compared with neutral CDs, 
complexation can be improved when the CD and the drug carry opposite charges but 
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may decrease when they carry the same charge. For many acidic drugs forming 
anions, the cationic (2-hydroxy-3-[trimethylammonio] propyl)-β-CD has acted as an 
excellent solubilizer. In the case of ionisable drugs, the presence of charge may play a 
significant role in drug/CD complexation and hence a change in the solution pH can 
vary the complexation constant. In general, ionic forms of drugs are weaker complex 
forming agents than their nonionic forms63 but in the case of mebendazole, the un-
ionized form was less included in HPβCD than the cationic derivative64. 
 
Temperature changes can affect drug/CD complexation. In most cases, increasing the 
temperature decreased the magnitude of the apparent complexation constant of the 
drug/CD complex and the effect was reported to be a result of possible reduction of 
drug/CD interaction forces, such as van der Waals and hydrophobic forces with rise 
of temperature. However, temperature changes may have negligible effect when the 
drug/CD interaction is predominantly entropy driven (ie, resulting from the liberation 
of water molecules hydrated around the charges of guest and host molecules through 
inclusion complexation)64 . 
 
The physicochemical properties of CDs, including their complexation ability, may be 
greatly affected by the type, number, and the position of the substituents on the parent 
CD molecule. The “degree of substitution” per se does not uniquely characterize a β-
CD derivative such as HPβCD. When produced under different conditions, the 
physicochemical properties of HPβCD samples with the same degree of substitution 
may not be identical owing to the possible occupancy of hydroxypropyl groups at 
different positions on the parent CD molecule. Since the purity of CD can have a 
significant effect on the final quality of the drug product and its marketability, it is 
necessary to have a proper understanding of the following term that is used in 
identification of CD purity65. 
 
“Degree of substitution” (DS) is the average number of substituted hydroxyls per 
glucopyranose unit of the CD ring. Since the number of reactive hydroxyls per mole 
of glucopyranose unit is 3, the maximum numbers of substituents possible for α-, β-, 
and γ-CDs are 18, 21, and 24, respectively65. 
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1.9.5 APPLICATIONS OF CYCLODEXTRINS IN THE 
PHARMACEUTICAL INDUSTRY 
The supramolecular characteristics, water solubility and wide availability of CDs, 
plus their generally low toxicity, make them ideal candidates for various industrial 
applications, especially for pharmaceutical applications. Improved water solubility, 
bioavailability, or metabolic stability, have allowed the reformulation of many drugs 
or to reduce the therapeutic dose of the active drug substance. Some studies on CD 
also suggest the direct therapeutic use of CDs, for example, to facilitate the 
elimination of a drug, like barbiturates from the blood circulation, or to sequester bile 
acids in the gastrointestinal tract in order to reduce the endogenous cholesterol levels. 
Unlike the more commonly used CD in pharmaceutics wherein CDs mainly act as 
excipients given together with an active drug substance, the direct therapeutic use of 
CDs is based on certain pharmacological effects resulting from in vivo CD-guest 
complexation66. Cyclodextrins are growing in use in the pharmaceutical industry and 
this is not limited to a particular dosage form, but has spread to almost every dosage 
forms66.  
 
The enhancing effects of CDs on the solubility, the dissolution rate, and the 
bioavailability of the drug tacrolimus after oral administration to rats were examined 
and compared with those after administration of a PROGRAF capsule containing the 
solid dispersion formulation of tacrolimus. The study suggests that dimethyl β-CD 
(DMβCD) is particularly useful in designing oral preparations of tacrolimus with an 
enhanced bioavailability and a reduced variability in absorption67. 
 
Cyclodextrins have effectively being used in ocular formulations either to enhance 
the solubility or to increase the viscosity in conjunction with polyvinyl alcohol (PVA) 
of the drug solution, so that the drug-eye contact is maximised. For example the 
complexation of pilocarpine prodrug with sulfobutyl ether beta-CD (SBE7-β-CD), 
with and without PVA, on the miotic response and eye irritation were studied in 
pigmented rabbits. The pilocarpine prodrug formed 1:1 inclusion complexes with 
variably substituted sulfobutyl ether derivatives of β-CD (SBE4-β-CD and SBE7-β-
CD), and 1:1 and 1:2 complexes with hydroxypropyl- β-CD (HPβCD) at pH 7.4. 
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Coadministered SBE7-β-CD eliminated the eye irritation due to the pilocarpine 
prodrug, but also decreased the miotic response. Ocular absorption of the prodrug was 
improved by increasing the viscosity of prodrug/SBE7-beta-CyD solution with PVA 
without inducing any eye irritation68.  
 
CD’s, and in particular HPβCD, have been found to improve the solubility and 
stability of drugs for nasal delivery. A recent study evaluated the potential use of 
HPβCD in the solubilisation and stabilization of prostaglandin E1 (PGE1). The 
solubility and chemical stability of PGE1 were found to improve significantly upon 
complexation with HPβCD. The nasal delivery of PGE1 from the complex 
formulation when studied in Wistar rats and compared with intravenous 
administration was found to cause a rapid decrease of blood pressure and exhibit an 
obvious dose-efficacy relationship, showing results nearly similar to those obtained 
for the intravenous route. Besides, the in vitro effect of the PGE1 complex on nasal 
mucociliary movement was also investigated with a toad palate model. The PGE1 
complex formulation exerted only minor effect on nasal mucociliary movement. The 
results of the study indicated that the PGE1-HPβCD complex formulation for nasal 
delivery is a very promising preparation with advantages such as rapid and effective 
absorption, good chemical stability, ease of administration, and minor nasal 
ciliotoxicity69. 
 
Cyclodextrins were used for rectal administration of some drugs like cefmetazole. For 
example in a study an inclusion complex of decanoic acid (DA) with alpha-
cyclodextrin (α-CD) was prepared as an additive of cefmetazole sodium (CMZ) 
suppository and rectally administered to rabbits. The complexation was examined by 
the phase solubility method, differential scanning calorimetry (DSC) and X-ray 
diffractometry. Plasma concentration and area under the curve (AUC) values of CMZ 
after rectal administration of a suppository containing DA/ α-CD complex to rabbits 
increased significantly over those without additive70. 
 
In recent years, CD’s have being evaluated for their solubility enhancement property 
for many insoluble drugs for parenteral use and researchers have found a wide range 
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of interest in using cyclodextrins for the same. For example, phenytoin was studied to 
increase its solubility by complexing it with varying concentrations of HPβCD and 
creating an entirely aqueous formulation with a pH significantly closer to physiologic 
pH (7.4). The two most promising formulations consisting of 40% HPβCD at pH 10.4 
and 20% HPβCD at pH 11.0 were selected for further study. Both formulations were 
aqueous with a significantly decreased pH compared to the original commercial 
formulation (Parke-Davis, pH 12.0). The formulations were also found to 
significantly decrease the tendency of phenytoin to precipitate in vitro. The tissue 
irritation potential of the 20% w/v HPβCD formulation at pH 11.0 was also reduced 
considerably compared to the commercial injection in a BALB/c mouse model71. 
 
In another study, a parenteral formulation of the water-insoluble benzodiazepine, 
diazepam, was developed. Different CD’s such as HPβCD, hydroxy-propyl-gamma-
cyclodextrin (HP-γ-CD), SBE-7-β-CD and maltosyl-beta-cyclodextrin (malt-β-CD) 
were used as alternatives to cosolvents to increase the solubility for parenteral 
injection. The greatest improvements in solubility (3.5 mg/ml in 40% CD) were found 
by adding HPβCD, or SBE-7- β-CD. A parenteral aqueous diazepam solution was 
prepared containing 10 mg diazepam/5 ml 30% HPβCD or SBE-7-β-CD solution. 
The preparations met the requirements for parenteral administration. Sterilisation was 
by filtration since autoclaving degrades the active compound. The stability with and 
without pH adjustment to pH 5, was evaluated during an 18 months period and no 
noticeable degradation was found72. 
 
The complexation technique in parenteral products has also been utilised to reduce 
toxicity and improve patient compliance. For example, mitomycin C (MMC), an 
anticancer drug, can cause severe dermatological problems upon injection. It can 
cause delayed erythema and/or ulceration occurring either at or distant from the 
injection site for weeks or even months after administration. In an attempt to reduce 
skin necrosis, complexation of MMC with HPβCD was studied in the presence and 
absence of mannitol in order to help increase patient compliance and acceptance. It 
was found that the mannitol present in the commercial formulation caused an increase 
in the binding of MMC to HPβCD. Also isotonicity adjustment of hypotonic MMC 
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formulations by the addition of normal saline did not change the degree of 
complexation with MMC. When evaluated for antitumor efficacy using the B-16 
melanoma cell model no difference in antitumor activity between the complexed and 
uncomplexed MMC formulations was observed73.  
 
1.10 NEED FOR PARENTERAL FORMULATION OF PRILOCAINE AND 
LIGNOCAINE  
Topical preparations of prilocaine hydrochloride and lignocaine hydrochloride have 
gained popularity over parenteral preparations commercially as well as in research, 
because of the ease in formulation and application by a patient. Parenteral local 
anaesthetics have had little research attention although they hold some advantages 
such as:  
1) Being used in localized treatment on any part of the body to block the nerves 
locally to alleviate the underlying pain.  
 
2) Providing a quick onset and longer duration of action compared to topical 
preparations.  
 
3) Being able to use such drugs in combination with other analgesic drugs. For 
example, parenteral injection of lignocaine with adrenaline is used in many surgeries. 
Similarly, in epidural anaesthesia for labour pain local anaesthetics alone were used 
for many years, but are now generally administered in lower concentrations with 
opioids to provide effective, synergistic analgesia while reducing a side effect of 
motor nerve block associated with local anaesthetics74.  
 
4) Producing very effective analgesia for a longer period of time post operatively 
when given at the conclusion of a surgery.  
 
Prilocaine and lignocaine show greater lipid solubility in their free base or molecular 
form. Lignocaine in its hydrochloride salt form has been used for producing a local 
anaesthetic effect parenterally. However, there has been very little research on 
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parenteral preparations of prilocaine and lignocaine in their molecular forms. These 
drugs in their free base form possess a solubility problem for parenteral formulation. 
These studies therefore seek to enhance the solubility of these drugs in their free base 
form. The expectation is to improve the solubilities of the drugs by formulating them 
as a solution using a complexing/solubilising agent. CD’s in particular HPβCD can be 
used as effective complexing agents. 
1.10.1 OBJECTIVES OF THIS STUDY 
 
1. To develop and validate an analytical high performance liquid chromatography 
method for three local anaesthetic drugs namely prilocaine hydrochloride, lignocaine 
hydrochloride and tetracaine hydrochloride. 
 
2. To evaluate HPβCD as complexing agent to increase the solubility of prilocaine 
and lignocaine as their free bases leading to parenteral formulation as solutions for 
rapid onset of action. 
 
3. To evaluate the solubility of prilocaine and lignocaine alone and in combination. 
 
4. To study the effect of complexation with HPβCD on the solubility of prilocaine 
and lignocaine alone and in combination. In addition the temperature dependency will 
be evaluated.  
 
5. To evaluate the complex formation using nuclear magnetic resonance spectroscopy 
(NMR). 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
Materials used were prilocaine hydrochloride (Lot no-39H0703, Sigma-Aldrich 
Chemie, Germany), lignocaine hydrochloride (Lot no-52774, ICN Biomedicals, Ohio, 
USA), tetracaine hydrochloride (Lot no 387H021, Hoechst Australia Ltd, Melbourne, 
Australia), lignocaine (lot No-074K1685, Sigma-Aldrich Chemie, Germany), 
hydroxy propyl β cyclodextrin (molecular weight - 1454.46 and degree of substitution 
- 5.5) (Lot no-Y1933, Cerestar®, USA) sodium hydroxide (pellets) (Lot no-28353, 
Merck Pty Ltd, Victoria), sodium carbonate anhydrous AR Grade (Lot no-FOG151, 
Asia Pacific Speciality Chemicals Ltd, NSW, Australia). All other reagents used were 
of analytical grade. 
 
The solvents used were deionised water, passed through a Milli Q Apparatus 
(Millipore Corporation, Bedford, USA), methanol (Labscan, Asia Co. Ltd, Bangkok, 
Thailand). All other solvents used were of HPLC grade.   
2.2 METHODS 
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2.2.1 ULTRAVIOLET (UV) SPECTROPHOTOMETRY FOR PRILOCAINE 
HYDROCHLORIDE, LIGNOCAINE HYDROCHLORIDE, AND 
TETRACAINE HYDROCHLORIDE 
 
A Hewlett-Packard diode array UV spectrophotometer (HP 8952A) California, USA 
was used to determine a common wavelength that could be used to detect the three 
local anaesthetic drugs simultaneously. The samples were diluted with Milli-Q water. 
Two wavelengths 220nm and 230nm were evaluated and 230nm was selected 
because the extinct coefficient of absorbance for all the three local anaesthetics 
namely prilocaine hydrochloride (HCl), lignocaine HCl and tetracaine HCl were 
found to be equal.  
 
 
2.2.2 METHOD DEVELOPMENT FOR PRILOCAINE HYDROCHLORIDE, 
LIGNOCAINE HYDROCHLORIDE, AND TETRACAINE 
HYDROCHLORIDE 
2.2.2.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 
An HPLC method was developed for prilocaine hydrochloride, lignocaine 
hydrochloride and tetracaine hydrochloride using a Waters Associates Model 501 
pump, IL, (Milford MA, USA) a 486 MS tunable absorbance detector and a Hewlett 
Packard integrator (HP 3396A), (CA, USA). An Apollo silica column, C18, 5µ, 150 x 
4.6mm ID, (Altech Associate, IL, USA) was used for separation of analytes. 
 
The mobile phase was 60/40 v/v of methanol and water in 20mM acetate buffer, 
pumped at the flow rate of 1.5mL/min. A 20µL injector loop, Rheodyne, (CA, USA) 
was used. The detection was carried out at 230nm using an attenuation of 0.13 milli 
absorbance units full scale. 
 
For each of the drugs 10mg was weighed accurately and dissolved in approximately 
25mL of water and the volume was made up to 100mL with water. Using this as 
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stock solution further dilutions were obtained over the concentration range of 1-
10µg/mL and injected onto the HPLC column. The calibration graph was prepared by 
plotting the peak areas against the concentration of each drug and correlation 
coefficients calculated. 
 
The lower limit of detection was determined using the range of concentrations for 
lignocaine hydrochloride, prilocaine hydrochloride, and tetracaine hydrochloride with 
the signal to noise response ratio of 2H/h where H is the height of the peak 
corresponding to the component and h = the absolute value of the largest noise 
fluctuation from the baseline of the blank solution. The wavelength was 230 nm and 
the attenuation was at 5.0. The intra- and inter-day precision was calculated with 
samples of n = 6 and concentrations of 0.001, 0.004, 0.008, and 0.010mg/mL, 
whereas interday precision was calculated with samples of n = 5 and concentrations 
of 0.004, 0.008, 0.010mg/mL respectively. 
2.2.2.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 
A second assay was developed with only prilocaine hydrochloride and lignocaine 
hydrochloride in combination.  
 
The mobile phase consisted of 70:30 v/v methanol water in 10mM phosphate buffer 
strength (pH = 5.5) pumped at 1.5mL/min through a 20µL injector loop. The 
detection was carried out at 230nm. 
 
The stock solution was prepared similar to the method described above and dilutions 
were made in the concentration range of 10-100µg/mL and injected onto the HPLC 
column. The calibration graph was prepared by plotting the areas under the curve 
against the concentration of the drugs and correlation coefficients calculated. 
2.2.3 PREPARATION OF PRILOCAINE AND LIGNOCAINE BASES 
2.2.3.1  METHOD I- PRILOCAINE BY FREEZE DRYING   
Prilocaine hydrochloride and lignocaine hydrochloride were precipitated using drop 
wise addition of 5M sodium hydroxide prepared as a stock solution. The precipitate 
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obtained for prilocaine was an oily liquid. The oily liquid was collected and washed 
with milli Q water and then it was freeze dried. It was then collected in an amber 
bottle to protect it from light and sealed. For further protection aluminium foil was 
wrapped around the bottle. 
 
The lignocaine base was obtained similarly and the precipitate was washed with water 
and filtered and dried at room temperature. It was then transferred to a glass bottle 
and sealed. 
2.2.3.2 METHOD II- PRILOCAINE BY EXTRACTION WITH 
DICHLOROMETHANE (DCM) 
The prilocaine obtained by the above method was not very pure and still contained 
traces of water after freeze drying, so an extraction method with dichloromethane 
(DCM) was employed to obtained prilocaine in pure form. This method involved 
addition of DCM along with 5M NaOH to prilocaine hydrochloride. The oily mixture 
was then shaken and washed with DCM thrice and the extract collected from the 
separator. Anhyderous sodium sulphate was added to DCM solution and left for one 
hour to take up the excess water content. Following filtration DCM was evaporated 
by distillation and the oil was transformed to the bottle.  
2.2.3.3  METHOD III- PRILOCAINE BY PRECIPITATION METHOD 
 
A third approach to obtain prilocaine in its base form involved using 0.5M sodium 
carbonate (Na2CO3) solution. To different concentrations of HPβCD solutions an 
excess amount of prilocaine hydrochloride was added, then 1mL of the Na2CO3 
solution was added to each concentration to effectively change prilocaine 
hydrochloride to prilocaine base. The solutions were then shaken for 24 hours for 
solubility evaluation. 
2.2.4 PREPARATION OF HPβCD SOLUTION 
 
A 30 % solution of HPβCD was prepared by the following procedure. 
HPβCD (molecular weight 1454.44 and degree of substitution 5.5) was triturated 
mildly in a glass mortar with a pestle to release the loose aggregates that might have 
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formed on standing. 30 g were then weighed accurately and the powder then 
transferred to a flask. A magnetic stirrer was used to stir the solution at all times. 
Small amounts of water were added each time and stirring adjusted to fast or medium 
as HPβCD went in solution. After all the HPβCD was in solution the stirring was 
continued for another 30 minutes to ensure a clear solution. It was transferred to a 
100mL volumetric flask and washings were added to the volumetric flask to make up 
the volume to 100mL. This solution was used as a stock solution for further studies. 
2.2.5 MAINTAINING THE pH OF PRILOCAINE BASE AND LIGNOCAINE 
BASE SOLUTION 
A sodium carbonate solution was prepared and added to the stated concentrations of 
HPβCD and prilocaine or lignocaine base to ensure that the drugs remained in their 
molecular form. The pH was maintained at 10, which was 2 pH units above the pKa 
(≈ 8.0). The pH meter used was a Microprocessor Bench pH Meter (HI 8417), Hanna 
instruments, USA. 
2.2.6 PREPARATION OF 0.5M SODIUM CARBONATE SOLUTION 
A 50mL solution of 0.5M sodium carbonate was prepared as follows. 
Sodium carbonate anhydrous (2.2g) was weighed accurately and dissolved with 
minimum quantity of Milli Q water. The solution was then transferred to a 50 mL 
volumetric flask and the washings transferred to the solution. This was then made to 
volume. 
2.2.7 PREPARATION OF 5M SODIUM HYDROXIDE SOLUTION 
The 5M stock solution of sodium hydroxide was prepared using following procedure. 
Sodium hydroxide was weighed accurately and transferred to a beaker. A minimum 
amount of Milli Q water was added to dissolve sodium hydroxide completely. This 
was then transferred to 100mL volumetric flask and the washings of the beaker added 
to it. The final volume was achieved by adding Milli Q water after bringing it to 25°C.  
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2.3 SOLUBILITY STUDIES OF PRILOCAINE AND LIGNOCAINE ALONE 
AND IN COMBINATION AT 25° C  
2.3.1 SOLUBILITY OF PRILOCAINE WITH HPβCD  
The solubility studies for prilocaine base and HPβCD were carried out using the 
phase solubility method. The pKa of prilocaine is 7.975 therefore the solubility studies 
were carried out at pH 10.0 using Na2CO3 buffer. The studies were carried out in the 
concentration range of 0-30% w/v of HPβCD. 
 
Excess amounts of prilocaine were added to glass vials containing different 
concentrations of HPβCD with Na2CO3 as buffer. The vials were sealed with screw 
caps and were shaken at 25 + 0.2°C for 24 h. A magnetic stirrer (Variomag model 20 
P) at the speed of 300 was used for the samples. After 24 hours, the samples were 
withdrawn from the vials and were centrifuged using an Eppendorf® mini spin 
centrifuge at 10,000 rpm for 10 min. The samples were then filtered through a GHP 
Acrodisc 13 mm Minispike Outlet 0.2µm syringe filters, (Gelman Pall, New York, 
America). The first drops of the sample were rejected and the rest collected and 
further dilutions prepared. Two dilutions of 0.1 in 10mL (1 in 10,000) were used. 
These samples were then injected on to the HPLC column for analysis. The mobile 
phase was 55:45 methanol:water with 20mM phosphate buffer at pH 5.5. The mobile 
phase was changed from 70:30 methanol:water to 55:45 methanol:water and the 
buffer remained the same. 
2.3.2 SOLUBILITY OF LIGNOCAINE WITH HPβCD  
 
The solubility studies with lignocaine base and HPβCD were determined using the 
method described in Section 2.3.1. Lignocaine has a pKa of 7.875, and therefore the 
solubility studies were carried out at pH 10.0 using Na2CO3. The concentration range 
for solubility studies with HPβCD was from 0-30% w/v in buffer. The mobile phase 
was 55:45 methanol:water with 20mM phosphate buffer at pH 5.5. 
 
 
2.3.3 SOLUBILITY OF PRILOCAINE AND LIGNOCAINE WITH HPβCD  
 
These studies were performed with a combination of prilocaine and lignocaine to 
determine the complexation with HPβCD. The solubility studies were carried using 
the same method as described in Section 2.3.1.  
 
The individual solubilities of prilocaine and lignocaine and the solubilities of each in 
combination were determined using the phase solubility diagram and the association 
constant, K1:1, was calculated from Equation 1 given below: 
 
                                            = 1:1K )1(0 SlopeS
Slope
−                                            Eq (16) 
 
where, S0 is the solubility in buffer at pH 10.0. 
2.3.4 SOLUBILITY STUDIES OF PRILOCAINE AND LIGNOCAINE 
ALONE AND IN COMBINATION AT ELEVATED TEMPERATURES 
 
Solubility studies for prilocaine, lignocaine, alone and in combination were carried 
out using the method described in Section 2.3.1. A shaking incubator (Labline 
Incubator), with the accuracy of (±0.2°C) was used to maintain temperatures. All the 
micropipettes, glasswares including the volumetric flasks, and the GHP Acrodisc 13 
mm Minispike Outlet 0.2µm Syringe filters along with the syringes were maintained 
at the same temperatures of 35 and 42°C respectively to avoid precipitation. 
 
The solutions of prilocaine base and lignocaine base alone and prilocaine with 
lignocaine were centrifuged using an Eppendorf® centrifuge, at 4000 rpm set at the 
temperatures of 35°C and 42°C respectively. The dilutions were done immediately 
using glasswares and filters maintained at the same temperatures. The mobile phase 
used remained the same with 20mM phosphate buffer at pH 5.5. 
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2.4 NUCLEAR MAGNETIC RESONANCE (NMR) 
One-dimensional 1H NMR spectra of prilocaine-HPßCD complexes and lignocaine-
HPßCD complexes were recorded with a 600.13 MHz Bruker AV-600 spectrometer 
at 25°C. The NMR’s were performed by Dr Lindsay Byrne (School of Biomedical, 
Biomolecular and Chemical Sciences, University of Western Australia, WA). 
Samples were dissolved in D2O. To each 1mL of 0.5M Na2CO3 buffer was added and 
the mixture freeze dried to remove moisture. The samples were prepared with and 
without HPßCD. The samples were finally redissolved in D2O prior to NMR analysis 
and sealed in ampoules. The chemical shifts (∆δ) were reported as ppm and were 
referenced to the residual water signal. 
 
3 RESULTS 
3.1 DETERMINATION OF UV SPECTRA FOR PRILOCAINE 
HYDROCHLORIDE, LIGNOCAINE HYDROCHLORIDE, AND 
TETRACAINE HYDROCHLORIDE 
 
The UV spectra for prilocaine hydrochloride, lignocaine hydrochloride, and tetracaine 
hydrochloride showed absorbance between 200 nm and 250 nm. The solvent used 
was Milli Q water and eqimolar concentrations of all the three drugs were used. The 
method is given in Section 2.2.1. The extinction coefficient of UV was found to be 
adequate at 230nm for all the three drugs. Representative UV spectra of all the three 
compounds are presented in Figure 8.  
 
 
 
Figure 8: UV spectra of prilocaine hydrochloride, lignocaine hydrochloride, and tetracaine 
hydrochloride 
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3.1.1 STANDARD CURVES OF PRILOCAINE HYDROCHLORIDE, 
LIGNOCAINE HYDROCHLORIDE, AND TETRACAINE 
HYDROCHLORIDE 
 
The calibration graphs for prilocaine hydrochloride, lignocaine hydrochloride and 
tetracaine hydrochloride were obtained using six different concentrations from 1-10 
µg/mL by the HPLC assay at 230 nm. The linear correlation coefficients R obtained 
for these three compounds were 0.999, 0.999, and 0.997 respectively for prilocaine 
hydrochloride, lignocaine hydrochloride, and tetracaine hydrochloride. Reproducible 
results were obtained with good separation of peaks. The retention times obtained for 
prilocaine hydrochloride, lignocaine hydrochloride, and tetracaine hydrochloride 
were 2.95 min, 6.38 min and 8.38 min respectively with a flow rate of 1.5 ml/min. 
The method is described in Section 2.2.2.1. Table 1 to Table 3 represents the six 
different concentrations of prilocaine hydrochloride, lignocaine hydrochloride, and 
tetracaine hydrochloride and Figure 9 to Figure 11 represent their calibration graphs. 
 
The HPLC assay was validated. The lower limit of detection for all the three 
compounds was carried out at attenuation 5.0 and was estimated at 0.1 µg/mL and 
varied below this concentration. The precision was calculated based on intraday and 
interday assays. The intraday assay was performed with samples of n = 6 of the same 
solutions at concentrations of 1.0, 4.0, 8.0, and 10.0 µg/mL. The intraday relative 
standard deviations (RSD) values for prilocaine hydrochloride, lignocaine 
hydrochloride and tetracaine hydrochloride were ranged from 0.43-2.90; 0.37-4.42, 
and 2.15-5.20 respectively. The interday RSD values for the above three drugs were 
based on n = 5 samples of the same solutions at the concentrations of 4.0, 8.0, and 
10.0 µg/mL. The RSD values obtained varied between 0.59-1.46 for prilocaine 
hydrochloride, 1.34-3.67 for lignocaine hydrochloride and 2.82-5.60 for tetracaine 
hydrochloride. The retention times remained the same for all the three compounds. 
The method is described in Section 2.2.2.1.  
 
Table 1: Concentrations and peak areas of prilocaine hydrochloride 
 
Concentration  
(µg/mL) 
Prilocaine hydrochloride area 
 at 230 nm x 10-5 
1 2.61 
2 5.01 
4 9.74 
6 14.6 
8 19.6 
10 24.3 
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Figure 9: Calibration graph of prilocaine hydrochloride at 230 nm by HPLC 
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Table 2: Concentrations and areas of lignocaine hydrochloride 
 
Concentration  
(µg/mL) 
Lignocaine hydrochloride area 
 at 230 nm x 10-5 
1 1.35 
2 2.62 
4 4.99 
6 7.51 
8 10.0 
10 12.4 
 
 
0 2 4 6 8 10
0
200000
400000
600000
800000
1000000
1200000
1400000
Y = A + B * X
A = 12447.74
B = 122983.79
R = 0.999
P
ea
k 
A
re
a 
of
 (L
ig
no
ca
in
e)
Concentration of Lignocaine hydrochloride (µg/mL)
 
 
Figure 10: Calibration graph of lignocaine hydrochloride at 230 nm by HPLC 
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Table 3: Concentrations and peak areas of tetracaine hydrochloride 
 
Concentration 
(µg/mL) 
Tetracaine hydrochloride area 
 at 230 nm  x 10-5 
1 2.85 
2 5.10 
4 8.61 
6 15.0 
8 20.1 
10 25.9 
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Figure 11: Calibration graph of tetracaine hydrochloride at 230 nm by HPLC 
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3.1.2 CALIBRATION ASSAYS FOR A COMBINATION OF PRILOCAINE 
HYDROCHLORIDE AND LIGNOCAINE HYDROCHLORIDE 
 
The second assay was developed for a combination of prilocaine hydrochloride and 
lignocaine hydrochloride in the range of 10-100 µg/mL (0.01-0.1 mg/mL) as 
described in Section 2.2.2.2. The wavelength used was 230 nm, and the coefficients 
of determination (R2) obtained were 0.9999 for both prilocaine hydrochloride and 
lignocaine hydrochloride. 
 
Table 4 shows the concentration range for prilocaine hydrochloride and lignocaine 
hydrochloride with the corresponding areas. Figure 12 represents the calibration 
graphs for prilocaine hydrochloride and lignocaine hydrochloride. 
 
Table 4: Concentrations and areas of prilocaine hydrochloride and lignocaine hydrochloride 
 
Concentration 
in mg/mL 
Prilocaine 
hydrochloride area 
at 230 nm x 10-5 
Lignocaine  
hydrochloride area 
at 230 nm x 10-5 
0.01 2.41 1.19 
0.02 4.02 1.96 
0.04 7.22 4.07 
0.06 10.84 6.09 
0.08 14.21 7.91 
0.10 17.37 9.81 
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Figure 12: Calibration graphs of prilocaine hydrochloride and lignocaine hydrochloride in 
combination at 230 nm by HPLC 
 
The mobile phase for the development of the first assay was 60:40 methanol:water 
with 20mM ammonium acetate buffer, whereas the mobile phase for the development 
of second assay was 70:30 methanol:water with 20mM phosphate buffer. The mobile 
phase concentration and buffer were changed to obtain sharper peaks and better 
results. The retention times for prilocaine hydrochloride and lignocaine hydrochloride 
changed from 2.95min and 6.38min to 2.92min and 6.30min respectively at the flow 
rate of 1.5 mL/min. 
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3.2 SOLUBILITY STUDIES 
The solubility experiments for prilocaine and lignocaine were carried out in buffer 
solution at pH 10.0 at 25.0, 35.0, and 42.0°C. Section 3.2.4 represents solubilities and 
association constants calculated for prilocaine with HPβCD and lignocaine with 
HPβCD individually and prilocaine and lignocaine with HPβCD in combination. The 
solubility temperature relationship was obtained by plotting log S (S = Solubility) 
against the reciprocal of temperature in Kelvin. This is shown in Section 3.2.5. 
3.2.1 SOLUBILITY STUDIES OF PRILOCAINE WITH HPßCD AT 25°C, 
35°C, AND 42°C 
High performance liquid chromatographic (HPLC) assays were used for the 
determination of prilocaine as described in Sections 2.3.1 and 2.3.4. The system 
provided a reproducible separation of prilocaine. The solubility curve of prilocaine in 
the presence of 0-30% HPβCD was obtained at 25°C. The solubility S determined 
over this concentration range of HPβCD and at 25°C was between 3.22-9.11 moles/L. 
At 35°C the solubility obtained was between 1.96-8.51 moles/L and at 42°C the 
solubility obtained was between 1.79-7.91 moles/L. The solubility So in water (buffer) 
was calculated from the extrapolation of the line on the graph. The amount of 
prilocaine was calculated taking its hydrochloride salt determination from the assay 
into consideration. The mobile phase used at this stage was 55:45 methanol:water 
with 20mM phosphate buffer at pH 5.5.The change in mobile phase was made to 
move the prilocaine peak away from the void peak, and the retention time was thus 
changed from 2.95 min to 3.21 min. 
3.2.2 SOLUBILITY DATA OF LIGNOCAINE WITH HPβCD AT 25°C, 35°C, 
AND 42°C 
 
Solubility data for lignocaine were determined by HPLC at 25°C, 35°C, and 42°C 
over 0-30% HPβCD by the method described in Sections 2.3.2 and 2.3.4. The system 
provided a reproducible separation of lignocaine with the retention time of 7.9 min. 
The change in mobile phase from 70:30 methanol:water to 55:45 methanol:water 
moved the retention time of lignocaine from 6.30 min to 7.9 min. The solubilities S of 
lignocaine obtained over 0-30% concentration range of HPβCD at 25°C were 
between 1.69-4.41 moles/L, at 35°C the S value was between 1.04-4.22 moles/L, and 
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at 42°C the S value was between of 1.04-4.55 moles/L. Similar to prilocaine the 
solubilities of lignocaine base were done taking into consideration its assayed 
hydrochloride salt and the solubility graphs obtained at all temperatures were AL type.  
3.2.3 SOLUBILITY DETERMINATION OF A COMBINATION OF 
PRILOCAINE AND LIGNOCAINE WITH HPβCD AT 25°C, 35°C, 
AND 42°C 
 
Solubilities of prilocaine and lignocaine at 25°C and at elevated temperatures were 
determined by HPLC using the method described in Sections 2.3.3 and 2.3.4. 
Reproducible results were obtained for prilocaine and lignocaine with retention times 
of 3.2 min and 7.9 min, respectively. The solubilities were obtained over the 
concentration range of 0-30% of HPβCD. At 25°C the solubilities S were between 
0.91-2.67 moles/L and 1.03-2.82 moles/L for prilocaine and lignocaine, respectively. 
At 35°C the solubilities for prilocaine and lignocaine were 0.64-2.89 moles/L and 
1.17-5.34 moles/L and at 42°C the solubilities for prilocaine and lignocaine were 
0.66-3.68 moles/L and 1.80-8.35 moles/L, respectively. The curves obtained were of 
the AL types (Figure 5). 
 
Compared to the solubility data obtained alone for prilocaine and lignocaine the 
overall decrease in solubility was obtained for prilocaine but an increase in solubility 
was obtained for lignocaine in combination at higher temperatures. 
 
3.2.4 SOLUBILITIES AND ASSOCIATION CONSTANTS OF PRILOCAINE 
AND LIGNOCAINE WITH HPβCD INDIVIDUALLY AND IN 
COMBINATION AT 25˚C, 35˚C AND 42˚C 
 
All the solubility isotherms obtained at different temperatures were classified as AL 
type implying formation of soluble complexes, and showing linear increase in 
solubilities as a function of HPβCD concentration. The association constants 
assuming a 1:1 stoichiometric complex ratio for each were calculated by Equation 
(17).  
 
                          )1(0 slopeS
slopeK s −=                                      Eq (17) 
 
The association constants were calculated on the basis of moles/L and plotted as a 
function of concentration of HPβCD on X axis to concentration of prilocaine and/or 
lignocaine on Y axis. Table 14 represents the association constants for prilocaine and 
lignocaine alone and in combination.  
Table 5 to  
Table 7 show the values of solubilities in moles/L for prilocaine at 25˚C, 35˚C, and 
42˚C.  
Table 8 to Table 10 show the values of solubilities in moles/L for lignocaine at 
elevated temperatures, and  
 
Table 11 to Table 13 shows the values of solubilities in moles/L for prilocaine and 
lignocaine in combination at elevated temperatures. Figure 13 to Figure 15 represent 
graphs of linear fit for prilocaine, Figure 16 to Figure 18 represent graphs of linear fit 
for lignocaine. Figure 19 and Figure 20 represents polynomial fit for prilocaine and 
lignocaine in combination and Figure 21 to Figure 24 represent graphs of linear fit of 
prilocaine and lignocaine in combination.   
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 Table 5: Solubility data for prilocaine determined at 25°C 
 
Concentration of HPßCD 
moles/L x 102 
Concentration of prilocaine 
moles/L x 102 
0.00  3.22  
3.44 4.11 
6.87 5.22 
10.30 6.17 
13.70 6.94 
17.20 8.16 
20.60 9.11 
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Figure 13: Solubility data for prilocaine at 25°C 
 
 
 
 
Table 6: Solubility data for prilocaine determined at 35°C 
 
Concentration of HPßCD 
moles/L x 102 
Concentration of prilocaine 
moles/L x 102 
0.00 1.96 
3.44 3.14 
6.87 4.44 
10.30 4.98 
13.70 7.04 
17.20 7.44 
20.60 8.51 
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Figure 14: Solubility data for prilocaine at 35˚C 
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 Table 7: Solubility data for prilocaine determined at 42°C 
 
Concentration of HPßCD 
moles/L x 102 
Concentration of prilocaine 
moles/L x 102 
0.00 1.79  
3.44 2.96 
6.87 3.51 
10.30 4.58 
13.70 6.23 
17.20 7.31 
20.60 7.91 
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Figure 15: Solubility data for prilocaine at 42˚C 
 
The molar solubilities of prilocaine-HPβCD complex were found to decrease with 
respect to the elevated temperatures. This suggests an exothermic reaction of the 
complex at higher temperatures which is enthalpically dependent on temperature. The 
complex is proposed to be formed between the hydrophobic moieties of the drug (the 
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aromatic ring of prilocaine) and HPβCD giving out heat in the process of 
complexation. 
 
Table 8: Solubility data for lignocaine determined at 25°C 
 
Concentration of HPßCD 
moles/L x 102 
Concentration of lignocaine 
moles/L x 102 
0.00 1.69  
3.44 1.89 
6.87 2.72 
10.30 3.38 
13.70 3.75 
17.20 4.17 
20.60 4.41 
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Figure 16: Solubility data for lignocaine at 25˚C 
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 Table 9: Solubility data for lignocaine determined at 35°C 
 
Concentration of HPßCD 
moles/L x 102 
Concentration of lignocaine 
moles/L x 102 
0.00 1.04  
3.44 1.33 
6.87 2.14 
10.30 2.76 
13.70 3.70 
17.20 4.29 
20.60 4.22 
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Figure 17: Solubility data for lignocaine at 35˚C 
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Table 10: Solubility data for lignocaine determined at 42°C 
 
Concentration of HPßCD 
moles/L x 102 
Concentration of lignocaine 
moles/L x 102 
0.00   1.04  
3.44 1.43 
6.87 2.11 
10.30 3.12 
13.70 4.17 
17.20 4.41 
20.60 4.55 
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Figure 18: Solubility data for lignocaine at 42˚C 
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Lignocaine do not show a significant change in molar solubility with lignocaine-
HPβCD complex at higher temperature to any extent. This suggests that the reaction 
is almost independent of temperature change. 
 
 
Table 11: Solubility data’s for prilocaine and lignocaine when in combination at 25°C 
 
Concentration of HPßCD 
moles/L x 102 
Concentration of prilocaine
moles/L x 102 
Concentration of lignocaine 
moles/L x 102 
0.00 0.91  1.03  
3.44 1.69 1.58 
6.87 2.29 2.20 
10.30 2.49 2.45 
13.70 2.66 2.59 
17.20 2.75 2.77 
20.60 2.67 2.82 
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Figure 19: Solubility data for prilocaine at 25˚C 
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Figure 20: Solubility data for lignocaine at 25˚C 
 
In Figure 17 and Figure 18, the first three points are linear, and the complex 
formation is increasing with increasing concentrations of HPβCD. The figures do not 
represent linear fit graphs. All the other S shaped concentrations of lignocaine and 
prilocaine were linearly fit without much error.  
 
Table 12: Solubility data’s for prilocaine and lignocaine when in combination at 35°C 
 
Concentration of  
HPßCD moles/L x 102 
Concentration of  
Prilocaine moles/L x 102 
Concentration of  
Lignocaine moles/L x 102
0.00 0.64  1.17  
3.44 0.84 1.33 
6.87 1.47 2.12 
10.30 1.45 2.67 
13.70 1.69 3.27 
17.20 2.13 4.42 
20.60 2.89 5.34 
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Figure 21: Solubility data for prilocaine at 35˚C 
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Figure 22: Solubility data for lignocaine at 35˚C 
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Table 13: Solubility data’s for prilocaine and lignocaine when in combination at 42°C 
 
Concentration of HPßCD 
moles/L x 102 
Concentration of prilocaine
moles/L x 102 
Concentration of lignocaine 
moles/L x 102 
0.00 0.66  1.80  
3.44 1.06 2.98 
6.87 1.67 3.95 
10.30 1.96 5.57 
13.70 2.45 6.38 
17.20 3.40 7.72 
20.60 3.68 8.35 
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Figure 23: Solubility data for prilocaine at 42˚C 
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Figure 24: Solubility data for lignocaine at 42˚C 
 
Table 14: Association constants (K) of prilocaine, lignocaine and prilocaine and lignocaine at 
different temperatures 
 
Drug  Temperature ˚C  Association Constants 
Prilocaine 25˚C 12.7 
 35˚C 23.2 
 42˚C 22.8 
Lignocaine 25˚C  9.9 
 35˚C 30.8 
 42˚C 21.1 
Prilocaine and Lignocaine 25˚C 27.5 and 19.0 
 35˚C 12.5 and 18.1 
 42˚C 27.3 and 17.5 
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In combination, the overall association constant values for prilocaine seem to 
decrease from 25°C to 35°C and then increase between 35°C and 42°C, whereas for 
lignocaine it seems to decrease with rise in temperatures. Individually for prilocaine, 
the association constants show an increase from 25°C to 35°C and then a slight 
decrease, the same is true for lignocaine too. This suggests that there is probably more 
than one mechanism involved in the formation of prilocaine-HPßCD and lignocaine-
HPßCD complexes. Also, it is noted that the association constants are relatively small 
in value. 
3.2.5 EFFECT OF ENTHALPY, ENTROPY AND FREE ENERGY ON 
SOLUBILITIES STUDIES OF PRILOCAINE AND LIGNOCAINE 
ALONE AND IN COMBINATION WITH HPβCD. 
 
The enthalphy (∆H°), entropy (∆S°), and the free energy (∆G°) for the drugs were 
calculated using the following equations, where RT = gas constant in joules/calories 
 
Log S = -∆H° + constant                                                                   Eq (18) 
               RT 
 
∆G° = -2.303RTlog S                                                                         Eq (19) 
 
∆S° = ∆H° - ∆G°                                                                                Eq (20) 
                 T 
 
 
The standard states were defined as unit molarity and the ∆H° was determined by 
plotting reciprocal of temperature (T) in Kelvin versus log solubilities for prilocaine 
and lignocaine. These data are listed in Table 15 to Table 18. 
 
 
 
 
Table 15: Log of solubilities of prilocaine at different temperatures 
 
Temperature K-1 Log Solubility of Prilocaine in moles/L  
 0 % HPβCD 10 % HPβCD 20 % HPβCD 30 % HPβCD
3.17 x 10-3 -1.769 -1.456 -1.208 -1.108 
3.25 x 10-3 -1.721 -1.357 -1.155 -1.071 
3.35 x 10-3 -1.495 -1.284 -1.161 -1.041 
 
3.17 x 10-3 3.25 x 10-3 3.35 x 10-3
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 Figure 25: Linear fit graph showing R values for Prilocaine. 
 
In figure 23 the linear fit graph showing R values for prilocaine obtained a linear 
relationship for 10% HPβCD and 30% HPβCD. R values greater than 0.95 were 
considered to give an adequate linear relationship following the van’t Hoff equation. 
The ∆H°, ∆G°, and ∆S° values are given in Table 19.  The log solubility of prilocaine 
seems to decrease with increase in temperatures as can be seen from Table 15. 
However the log solubility values are increased with increase in concentration of 
HPβCD. This suggests that although solubility of prilocaine is temperature dependent 
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an increase in solubility is obtained at higher concentrations of HPβCD. The enthalpy 
and entropy values as in Table 19 give an idea of how the complexation of prilocaine-
HPβCD occurs. As is seen in Table 19 the ∆H° values are relatively similar and small 
difference exists between enthalpies dependent upon the concentration of HPβCD. A 
greater difference in entropy values was obtained and this suggests that complexation 
is governed more by entropy rather than enthalpy. Hence the orientation of the drug 
in the complex may be an important factor. 
 
Table 16: Log of solubilities of lignocaine different temperatures 
 
Temperature K-1 Log Solubility of Lignocaine in moles/L  
 0 % HPβCD 10 % HPβCD 20 % 
HPβCD 
30 % HPβCD 
3.17 x 10-3 -2.000 -1.678 -1.387 -1.347 
3.25x 10-3 -2.000 -1.699 -1.432 -1.377 
3.35 x 10-3 -1.796 -1.596 -1.432 -1.367 
 
3 .10  x  10 -3 3 .20x 10 -3 3 .35  x  10 -3
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Figure 26: Linear fit graph showing R values for lignocaine. 
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In Figure 24 the linear fit graph shows that solubility of lignocaine increases with 
increase in concentration of HPβCD, however it is not very significant change and 
therefore when the temperature was raised almost no change in the log solubility 
values were obtained when plotted against absolute temperature. The nonlinear 
relationship was obtained for all the concentrations of HPβCD and thus van’t Hoff’s 
equation was not followed between any two of the temperatures.  
 
Table 17: Log solubilities of prilocaine and lignocaine in combination at different temperatures 
 
Temperature K-
1 
Log Solubility of Prilocaine in presence of Lignocaine in moles/L 
 0 % HPßCD 10 % HPßCD 20 % HPßCD 30 % HPßCD 
3.17 x 10-3 -2.174 -1.795 -1.619 -1.444 
3.25 x 10-3 -2.193 -1.833 -1.770 -1.540 
3.35 x 10-3 -2.046 -1.641 -1.575 -1.574 
 
3.10 x 10-3 3.20 x 10-3 3.35 x 10-3
-2.2
-2.1
-2.0
-1.9
-1.8
-1.7
-1.6
-1.5
-1.4
Linear fit graph of prilocaine in presence of lignocaine
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Figure 27: Linear fit graph showing R values for Prilocaine in presence of Lignocaine. 
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Linear fit graph showing R values for Prilocaine in presence of Lignocaine that shows 
the complex formation of prilocaine in presence of lignocaine with HPβCD. The log 
solubility seems to increase with increase in concentrations of HPβCD from 0 to 30%. 
However the log solubility was found to decrease with increase in temperature. The 
concentration of HPβCD (0%-20%) showed nonlinear relationships whereas a linear 
relationship was obtained for 30% HPβCD and was associated with the negative ∆H°. 
The ∆H° value obtained was very small and ∆S° value was very large suggesting 
hydrophobic interactions during complex formation. 
 
Table 18: Log solubilities of lignocaine in combination with prilocaine at different temperatures 
 
Temperature K-1 Log 
Solubility 
of Lignocaine in presence of  Prilocaine  
in moles/L 
 0 % HPßCD 10 % HPßCD 20 % 
HPßCD 
30 % HPßCD 
3.17 x 10-3 -1.745 -1.408 -1.201 -1.081 
3.25 x 10-3 -1.958 -1.678 -1.495 -1.276 
3.35 x 10-3 -2.076 -1.748 -1.677 -1.641 
 
3 . 1 7  x  1 0 - 3 3 . 2 5  x  1 0 - 3 3 . 3 5  x  1 0 - 3
- 2 . 2
- 2 . 0
- 1 . 8
- 1 . 6
- 1 . 4
- 1 . 2
- 1 . 0
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Figure 28: Linear fit graph showing R values of Lignocaine in presence of Prilocaine. 
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Linear fit graph showing R values of lignocaine in presence of prilocaine suggesting 
that a linear relationship is followed at all the concentrations of HPβCD and van’t 
Hoff equation is followed. The log solubility increases with increase in concentration 
of HPβCD and with rise in temperature. However when ∆H° and ∆S° values were 
calculated (Table 19) a small positive ∆H° and a large ∆S° was obtained suggesting 
that the complex formation is driven by entropy. The negative R values gave a 
negative intercept. 
 
Table 19: Thermodynamic parameters of prilocaine and lignocaine following a linear 
relationship at 25°C, 35°C and 42°C 
 
Prilocaine ∆H° Jmol-1 ∆G° Jmol-1 ∆S° JK-1mol-1 
0% HPßCD -2.62 20761.11 -65.92 
10% HPßCD -1.65 14978.25 -47.55 
30% HPßCD -0.64 9099.50 -28.89 
    
Prilocaine in presence of 
Lignocaine 
∆H° Jmol-1 ∆G° Jmol-1 ∆S° JK-1mol-1 
30% HPßCD -25.20 247650.25 786.27 
    
Lignocaine in presence 
of Prilocaine 
∆H° Jmol-1 ∆G° Jmol-1 ∆S° JK-1mol-1 
0% HPßCD 2.44 -10063.91 -39.94 
10% HPßCD 2.38 -11487.31 -36.46 
20% HPßCD 3.84 -25215.26 -80.04 
30% HPßCD 4.50 -31825.02 -101.02 
 
 
 
 
 
 
3.3 INVESTIGATION OF HPßCD COMPLEX FORMATION WITH 
PRILOCAINE AND LIGNOCAINE BY NMR 
Complex formation of prilocaine and lignocaine with HPßCD was also investigated 
by NMR. NMR spectroscopy is one of the most used techniques to obtain information 
about the geometry of inclusion complexes. The chemical formula of prilocaine is 
C13H20N2O and the chemical formula of lignocaine is C14H22N2O. Figure 29 and 
Figure 30 represents the chemical structures of prilocaine and lignocaine for 
evaluating the chemical shift and changes in characterisation of peaks obtained by 
complexation with HPßCD. Table 20 and Table 21 represents the protons of 
prilocaine and lignocaine involved in a chemical shifts with and without HPßCD and 
their ∆δ (ppm). 
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Figure 29: Chemical structure of prilocaine. 
 
Table 20: 1H NMR showing chemical shift for prilocaine with and without HPßCD 
 
Assignments Prilocaine without 
HPβCD (ppm) 
Prilocaine with  
HPβCD (ppm) 
∆δ 
(ppm) 
A- triplet 0.905 0.763 - 0.142 
B- multiplex 1.515 1.373 - 0.142 
C- triplet 2.569 2.424 - 0.145 
D- doublet 1.370 1.235 - 0.135 
E- quadruplet 3.505 * * 
F- singlet 2.214 2.132 - 0.082 
G and I- broad doublet 7.296 7.113 - 0.183 
H and J- broad multiplex 7.297 7.193 - 0.104 
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Figure 30: Chemical structure of lignocaine 
 
Table 21: 1H NMR showing chemical shift for lignocaine with and without HPßCD 
 
Assignments Lignocaine without  
HPβCD (ppm) 
Lignocaine with  
HPβCD (ppm) 
∆δ  
(ppm) 
A – triplet 1.113 * * 
B – quadruplet 2.710 2.570 - 0.140 
C – singlet 3.404 * * 
D – singlet 2.180 2.062 - 0.118 
E – broad doublet 7.180 7.033 - 0.147 
F – broad multiplex 7.218 7.065 - 0.153 
 
An (*) means no chemical shift was obtained. 
 
In the 1H-NMR peak assignments for free and complex prilocaine and lignocaine the 
corresponding shifts ∆δ is represented as ∆δ = δ (complex) – δ (free). The prilocaine 
and prilocaine HPßCD and ligocaine and lignocaine HPßCD complexes were 
prepared as previously described in Section 2.4 and were dissolved in D2O. Chemical 
shifts were given in parts per million relative to the signal obtained. 1H NMR studies 
showed upfield shifts for all the protons from A-H for prilocaine and A-F for 
lignocaine.  
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igure 31 (a), (b), (c), (d), and (e) represents the NMR peaks where, 
e 
ith HPβCD 
ith HPβCD 
 
 
F
(a) NMR of HPβCD 
(b) NMR of prilocain
(c) NMR of prilocaine w
(d) NMR of lignocaine 
(e) NMR of lignocaine w
Fig 29 (a) NMR of HPßCD 
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Fig 29 (b) NMR of Prilocaine  
 
A- 0.905 
B- 1.515 
C- 2.569 
D- 1.370 
E- 3.505 
F- 2.214 
G- 7.296 
H- 7.297 
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 Fig 29 (c) NMR of Prilocaine with HPßCD 
 
A- 0.763 
B- 1.373 
C- 2.424 
D- 1.235 
E- * 
F- 2.132 
G- 7.113 
H- 7.193 
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Fig 29 (d) NMR of Lignocaine  
 
A- 1.113 
B- 2.710 
C- 3.404 
D- 2.180 
E- 7.180 
F- 7.218 
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Fig 29 (e) NMR of Lignocaine with HPßCD 
 A- * 
B- 2.570 
C- * 
D- 2.062 
E- 7.033 
F- 7.065 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: 1H NMR spectra of (a) HPßCD, (b) prilocaine, (c) lignocaine, (d) prilocaine-HPßCD 
complex and (e) lignocaine-HPßCD complex. 
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3.4 GRAPHICAL COMPARISON OF CHEMICAL SHIFTS OF PROTONS 
OF PRILOCAINE AND LIGNOCAINE IN THE PRESENCE AND 
ABSENCE OF HPβCD 
Chemical shifts of protons for prilocaine and lignocaine in the presence and absence 
of HPßCD are represented graphically in Figure 32 and Figure 33. The chemical shift 
and change in peak character was observed where complexation for prilocaine and 
lignocaine occurred through HPßCD. The NMR’s are given in Section 3.3. The peak 
suppression due to complexation for prilocaine with HPßCD is represented 
graphically in Figure 30.  At ‘E’ no chemical shift was observed.  
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Figure 32: Chemical shift of prilocaine in the presence and absence of HPßCD 
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Lignocaine with HPβCD showed changes in peak characterisation at ‘B’, ‘D’, ‘E’ and 
‘F’ suggesting the formation of complex through inclusion of lignocaine in the torus 
structure of HPβCD. Figure 31 represents the graphical  interpretation of lignocaine-  
HPβCD and shows that at ‘A’ and  ‘C’ no chemical shift is observed. 
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Figure 33: Chemical shift of lignocaine protons in the presence and absence of HPßCD 
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4 DISCUSSION 
The validated method was initially developed to separate three local anaesthetic drugs 
namely prilocaine HCl, lignocaine HCl, and tetracaine HCl. The R values obtained 
for prilocaine HCl, lignocaine HCl, and tetracaine HCl were 0.999, 0.999, and 0.997 
respectively. Tetracaine HCl was later excluded from the studies as complex 
formation with the combination of three drugs seemed unfeasible. A second method 
was then developed only for prilocaine HCl and lignocaine HCl. Reproducible results 
were obtained and the next step than was to determine the solubility of prilocaine and 
lignocaine and to enhance this by complexing it with HPβCD. 
 
Solubility is the basic requirement for any formulation that needs to be prepared in a 
solution form. Also solubility enhancement has broad implications in parenteral 
formulation design. Although many drugs are fairly soluble in aqueous solutions, 
lipophilic drugs impose a solubility problem to be able to formulate as a solution. A 
variety of solubilisation techniques has been studied and widely used including pH 
adjustment, cosolvent addition, surfactant addition and cyclodextrin addition40. 
Complexation with cyclodextrins is now a commonly used technique to improve drug 
solubility from number of other methods.  
 
Although ionised drugs show greater aqueous solubility, the unionised form 
(molecular form) of drugs can be solubilised by complexation and pH adjustment. 
Prilocaine and lignocaine have the pKa values of 7.9 and 7.8 respectively therefore 
the pH of the solutions were maintained at 10.0.  The lipophilic form of the drug may 
be advantageous for rapid onset of action if sufficient can be delivered in a solution 
formulation. 
 
Complex formation with CD involves the release of enthalpy-rich water from the CD 
cavity as the main driving force for complexation. Other mechanisms that may be 
involved in complex formation include van der Waals interactions, hydrogen bonding 
and hydrophobic interactions. In the case of α-CD, release of ring strain is also 
thought to be involved with the driving force for compound–CD interaction76. 
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Accordingly, different types of solubility isotherms are obtained as a result of 
complex formation with cyclodextrins which include AL, AP, and AN types of 
isotherm. The AL type of solubility isotherms was obtained for prilocaine and 
lignocaine with HPβCD. As mentioned above, the solubilities of prilocaine and 
lignocaine at higher temperatures were found to differ individually. One reason that 
can be proposed for an unexpected decrease in solubility of prilocaine at higher 
temperatures is its existence as R and S stereoisomer’s. The spatial arrangements of 
these two stereoisomers of prilocaine at higher temperatures may limit its complex 
formation with HPβCD and affects its solubility and perhaps potency77.  
 
Many drugs studied in combination have either shown increase in solubility as 
expected or variations from solubility. Sometimes not the other drug but the cosolvent 
used along with the complexing agent was found to compete with drug for the entry 
into the HPβCD cavity decreasing the drug solubility. This has been found with the 
drug fluasterone where an overall decrease in solubility and complex formation 
occurred when complexed with HPβCD40. Although cosolvent can act as a space 
regulating molecule for the drug molecule to fit into cyclodextrin, research done by 
Pitha et al. reported that the complexation constant of testosterone with HPβCD was 
10,000 fold lowered in 80% ethanol than in water40.  
 
Almost similar solubility constants were obtained for prilocaine in combination with 
lignocaine when complexed with HPβCD. The solubility of prilocaine was again 
found to be decreased in the presence of lignocaine with a rise in temperature, but the 
differences obtained for solubilities between the temperatures were very small.  The 
above proposed mechanism may hold true for prilocaine solubility in combination or 
it may be true again that in the presence of the other drug prilocaine showed 
hinderence in complex formation and thus its solubility decreased. However 
lignocaine solubility was found to rise effectively with rise in temperature as 
compared to its no change in solubility individually. It seems that in combination with 
prilocaine, lignocaine solubility was favoured.  
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Although prilocaine and lignocaine share structural similarities the difference’s in 
solubility of these two drugs individually and in combination suggests varying 
patterns of complexation and the possibility of specific interactions or mixed modes 
of binding between different components or functional groups in the structure of the 
substrate and cyclodextrin. Earlier studies have reported the varying modes of 
complex formation with the relatively common structures of steroids, when 
complexed by SBE-7-β-CD, which only differed in the D ring substituents78.  
 
Thus the theory of mixed mode interactions for complex formation with HPßCD in 
for prilocaine and lignocaine individually and in combination at higher temperatures 
cannot be overruled.  
 
The variability in complex formation with cyclodextrins can again be explained by 
the well documented experimental work of two hydrophobic drugs, indomethacin and 
griseofulvin, which have structural resemblance to each other. This was proved by 
various methods such as X-ray powder diffraction, modulated temperature differential 
scanning calorimetry and dissolution tests, which were used for the characterisation 
of solid state inclusion complexes of indomethacin and griseofulvin with β-CD, α-CD, 
and γ-CD in PEG 6000. The results showed that for griseofulvin no complex was 
formed with β-CD and this was partly represented by the steric hindrance of 
griseofulvin, whereas indomethacin in the presence of polyethylene glycol 6000 
(PEG 6000) showed complex formation with β-CD and γ-CD, but not with α-CD. 
This was because α-CD showed good complexation with PEG 6000 in the melt and β-
CD and γ-CD showed minimum interaction with the polymer and therefore could 
complex with indomethacin76. 
 
The variability of CD-drug complex can be further explained regarding to polymer 
complexation with different types of CD’s. An aqueous solution of propylene glycol 
at low concentrations reduces the CD complexation of some drugs by acting as a 
competing guest molecule79. The α-CD forms complexes with PEG of various 
molecular weights but, β-CD does not form complexes with PEG. This might 
promote the inclusion complex formation for the drug in this type of CD. It was 
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shown that β- and γ-CD form complexes with other polymers like polypropylene 
glycol (PPG) and polyisobutylene, while α-CD does not form complexes with either 
of these polymers. β- and γ-CD might therefore be more alike concerning their 
interactions with different polymers80. Selection of the correct CD’s therefore favours 
the complex formation with the drug molecule further enhancing its solubility effect. 
 
In yet another study it was found that co-administration of hydroxypropyl methyl 
cellulose (HPMC) with SBE-7-β-CD sodium salt reduced the amount of β-CD needed 
in a solid dosage form of glibenclamide, without reducing its bioavailability and 
solubility. Compared to formulation without HPMC, more of the β-CD was needed 
for inclusion formation though the bioavailability was not affected in both of the 
formulations81. 
 
The above findings in regard to complex formation with HPβCD suggest that 
different interactions at the molecular level exist during complexation and use of 
different CD’s with different substituents can give different results. These findings 
lend support to the results obtained for solubilities of prilocaine and lignocaine. 
 
The relative thermodynamic parameters for the complexation process are the standard 
free energy change (∆G°), the standard enthalpy change (∆H°), and the standard 
entropy change (∆S°). As revealed in the earlier data complexation of prilocaine and 
lignocaine with HPβCD was accompanied by negative ∆H°, reflecting an exothermic 
process driven enthalpically. The enthalpy driven processes are associated with 
intermolecular interactions via hydrogen bonding and van der Waal’s interactions. 
However the ∆H° and ∆S° values were not very significant for prilocaine and 
lignocaine and overall they suggested that an endothermic reaction is involved driven 
by entropy and involving hydrophobic interactions. Also nonlinearity observed at 
some of the HPβCD concentrations suggested that van’t Hoff’s equation was not 
followed. 
 
Lignocaine alone and prilocaine in the presence of lignocaine showed non-linearity 
for the van’t Hoff equation. It was noted that the solubilities were little affected by 
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temperature changes. But for lignocaine in presence of prilocaine the rise in 
solubilities was seen with rise in temperature and all the concentrations of HPβCD 
showed that van’t Hoff equation was essentially followed as R value was above 0.95 
for all. 
 
The thermodynamic parameter ∆H° was relatively small as little change occurred in 
the solubility with a rise in temperature for both prilocaine and lignocaine. On the 
other hand ∆S° values were significantly large and so it can be said that complex 
formation was largely governed by entropy change. 
 
The solubilities obtained for lignocaine individually showed little temperature effect, 
whereas in combination the solubilities seemed to increase to a greater extent. In 
contrast the solubilities of prilocaine decreased individually and also in combination. 
This indicated that more than one mechanism is involved in the complexation process 
and there may be a structural influence and stereoisomeric factors playing a role 
along with the hydrogen bonding giving varied solubility results. Also the theory 
proposed below can give an insight between the solution and the drug-HPβCD (guest-
HPβCD) complex formation and the difference that exists in the mechanism of 
complexation. 
 
The thermodynamic effects of β-CD and factors that result in different patterns of 
complexation apart from what is expected is well discussed in the complex formation 
of β-CD with different derivatives of azoalkanes leading to a host-guest relationship. 
Derivatives of the azoalkane 2,3-diazabicyclo[2,2,2]oct-2-ene, 1,4-dialkyl, 1,4-
dichloro, 1-hydroxymethyl, 1-aminomethyl, and 1-ammoniummethyl substituents 
form host-guest inclusion complexes with β-cyclodextrin. In that experimental work 
they were employed as probes to assess substituent effects on the kinetics and 
thermodynamics of this complexation by using time-resolved and steady state 
fluorimetry, UV spectrophotometry, induced circular dichroism (ICD) measurements, 
and 1H NMR spectroscopy. The ICD was employed for the assignment of the 
solution structures of the complexes, in particular the relative orientation of the guest 
in the host (co-conformation). 
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Accordingly the structure of the β-CD and 1-aminomethyl complex was assumed to 
give rise to the negative ICD signal, but the ICD spectra revealed that the complex of 
azoalkane 1-aminomethyl differed from the other derivatives and gave rise to an ICD 
band, which was significantly distorted, and also showed a bathochromic shift 
relative to the UV spectrum. Moreover, the ICD of 1-amino methyl complex showed 
a small positive component at shorter wavelengths in addition to the stronger negative 
ones. These irregularities suggested that a large co-conformational variability exist, 
which meant that complexes with different tilt angles may have been present in 
solution. It was found based on the results that for 1-aminomethyl, in contrast to 1-
hydroxymethyl and 1-ammoniummethyl, the co-conformational spaces were not 
restricted by hydrogen bonding with the upper rim. The co-conformers with different 
tilt angles had quite different UV spectra (which reflected the depth of inclusion into 
the nonpolar environment) and ICD effects (which reflected the geometrical 
alignment with respect to the azo chromophore) and, thus, accounted for the observed 
shifts for 1-aminomethyl.  
 
The hydrophobicity order of the examined guest molecules was established to be 1,4-
dichloro > 1,4-dialkyl > 2,3-diazabicyclo[2,2,2]oct-2-ene > 1-aminomethyl > 1-
hydroxymethyl and > 1-ammoniummethyl. A higher hydrophobicity was expected to 
result in a larger binding constant. Azoalkane 1,4-dialkyl  did not show a higher 
binding affinity than 2,3-diazabicyclo[2,2,2]oct-2-ene despite its higher 
hydrophobicity. This was rationalized in terms of the solution structures, which 
indicated that the lateral co-conformation was energetically most favourable one and 
could not be attained for 1,4-dialkyl. Instead, a frontal mode of inclusion was adapted 
for 1,4-dialkyl which was energetically less favourable. This lessened the increased 
driving force due to its higher hydrophobicity and resulted in essentially the same 
binding constant as for 2,3-diazabicyclo[2,2,2]oct-2-ene.  
 
Regarding the hydrophilicity generally, the more hydrophilic guests 1-aminomethyl 
and 1-ammoniummethyl should show lower binding constants than 2,3-
diazabicyclo[2,2,2]oct-2-ene and 1,4-dichloro as the ionic ammonium guest displays 
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the weakest binding. The difference in binding constants between 1-aminomethyl 
(250 M-1) and 1-ammoniummethyl (20 M-1) was in line with the general observation 
that the ionization of the guest causes a destabilization of CD complexes in water. But 
for the hydroxyl and ammonium derivatives 1-hydroxymethyl and 1-
ammoniummethyl, for which hydrogen bonding was presumed, it actually showed a 
weaker binding than the amino derivative, for which hydrogen bonding to the CD 
should have not played a role at all. This could be adequately accounted for in terms 
of guest hydrophobicity and a change in the co-conformation due to the introduction 
of bridgehead substituents82. 
 
The above mentioned findings support the variability in solubilities obtained for 
prilocaine and lignocaine and confirms that expected solubilities may not be obtained 
as a result of complex formation with HPβCD and that variation in results can be 
obtained due to structural differences between two drugs, intermolecular changes 
because of the presence of other drug in combination and/or sterioisomeric 
interferences and again the type of structural interactions taking place between the 
guest molecule and CD. Competitive binding between prilocaine and lignocaine for 
CD sites may be another factor. 
 
To study the complex formation of prilocaine and lignocaine with HPβCD further, 
NMR spectra’s for prilocaine and lignocaine were obtained at 600 Hz. The NMR 
suggested that different chemical shifts were involved for both prilocaine and 
lignocaine with few similarities. The NMR details of free prilocaine and prilocaine-
HPβCD complex and lignocaine and lignocaine-HPβCD were presented earlier in 
Section 3.3. 
 
The NMR of prilocaine showed involvement of aromatic protons, along with other 
methene and methyl groups and the NMR of lignocaine showed involvement of 
aromatic protons along with aromatic methyl and ethyl amide groups. 
 
When lignocaine HPβCD NMR was compared with the similar NMR studies of 
another local anaesthetic benzocaine and β-CD the results have shown similarites 
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between the complex formation that occured at ethyl-CH3, ethyl-CH2, and at the 
aromatic protons H1-H6 for benzocaine83.  
 
In another study done for the selectivity in the binding and detection of charge diffuse 
ions, the neutral, lipophilic peralkylated cyclodextrin derivatives were found to 
selectively bind the onium ions like R-NH3+ and NMe4+. When local anaesthetics 
such as lignocaine were studied in the presence of 2, 6- didodecyl –β-cyclodextrin as 
the sensing ionophore it gave a Nernstian response at the NH+Et2 binding site.  
 
The response was obtained down to 10-5.6 mol dm-3 concentrations. The nernstian 
behaviour obtained showed that NH+Et2 ion is potentially active site for binding with 
the cyclodextrin resulting in complex formation. The study showed that neutral, 
lipophilic cyclodextrin derivatives can be used for the chemoselective detection of a 
variety of aryl and alkyl ammonium ions84. Similarly a chemical shift of a triplet and 
a multiplet NH+Et2 for lignocaine HPβCD was observed at the NH+Et2 binding site 
along with the chemical shifts of aromatic protons and aromatic methyl group. This 
would be less likely at high pH values used in this study. 
 
The NMR details of prilocaine located from earlier studies in the literature found the 
involvement of chiral carbon. The chiral solvating agent, 2,2,2-trifluoro-1-(9-anthryl) 
ethanol, was used to determine the diasteriosmeric interactions and assignments of the 
configuration was based on the relative field position of resolved enantiomeric  
signals85.  
 
At present preparationjs of parenteral dosage forms of local anaesthetics in solution is 
acheived by means of their hydrochloride salts. Therefore the pH of these 
preparations can be as low as 3.0 to 4.5. A possible precipitation of the base at the 
injection site may occur due to an increase in pH to the tissue pH after injection 
exacerbated by a lowering of free base solubility at body temperature86. A 
formulation therefore of higher pH range say about pH 10.0, will keep the drugs in 
unprotonated form and intact in a complex until it reaches its site of action. Tissue 
and blood pH will have little effect on the drug formulation as they are not used in 
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their salt forms. Research has shown that the pH of above 11.5 and below 4.0 can 
produce some pain during administration of anaesthetics, but no pain was observed in 
individuals at pH 10.0. Therefore the parenteral formulation of prilocaine and 
lignocaine base at pH 10.0 would be safe for parenteral purpose87.  
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5 CONCLUSIONS 
 
Prilocaine and lignocaine share structural similarities as both are amide type local 
anaesthetics. It was expected that similar solubility results would be obtained for both 
individually and in combination, but the difference’s in solubility of these two drugs 
individually and in combination suggests varying patterns of complexation and the 
possibility of specific interactions or mixed modes of binding between different 
components or functional groups in the structure of the substrate and cyclodextrin. 
 
The complex formation showed that entropy rather than enthalpy was governing the 
reaction for complexation form individually and in combination for both prilocaine 
and lignocaine as ∆H° values were very small. There was only a small temperature 
effect on solubility limiting the accuracy with which these effects could be described 
 
The AL type solubility isotherm was obtained for all the solubilities suggesting that 
binding involves 1:1 association between guest and CD molecule. 
 
The NMR data showed that aromatic rings of both prilocaine and lignocaine are 
involved in complex formation apart from the methene and methyl groups for 
prilocaine and ethyl amide and aromatic methyl groups for lignocaine. 
 
Solubilities of prilocaine determined over the concentration range of 0-30% HPβCD 
were found to increase with increasing concentration of HPβCD and solubilities of 
lignocaine showed little increase with increase in concentration of HPβCD. With the 
rise in temperature the solubilities of prilocaine decreased, whereas again temperature 
showed little effect on the solubilities of lignocaine. The solubilities obtained for 
prilocaine at the temperatures 25°C, 35°C, and 42°C were between 3.22-9.11 moles/L, 
1.96-8.51 moles/L and 1.79-7.91 moles/L respectively. The solubilities obtained for 
lignocaine at the temperatures from 25°C-42°C were 1.69-4.41 moles/L, 1.04-4.22 
moles/L and 1.04-4.55 moles/L respectively. 
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In combination, the solubilities of prilocaine and lignocaine showed variation in 
complexation with HPβCD from the solubilities obtained individually. Prilocaine in 
combination showed increase in solubility with increase in concentration of HPβCD 
but showed decrease in solubilities with rise in temperature. Lignocaine on the other 
hand showed increase in solubilities with increase in concentrations of HPβCD and 
with rise in temperatures. The solubilities obtained for prilocaine at 25°C, 35°C, and 
42°C were 0.91-2.67 moles/L, 0.64-2.89 moles/L and 0.66-3.68 moles/L respectively 
and the solubilities obtained for lignocaine were 1.03-2.82 moles/L, 1.17-5.34 
moles/L and 1.80-8.35 moles/L respectively.  
 
From the data obtained in combination of prilocaine and lignocaine one can say that 
solubilities of prilocaine showed little change with the rise in temperature but the 
solubilities of lignocaine was found to increase in contrast to its solubilities obtained 
individually. 
 
A pH of 10.0 used for the development of parenteral formulation should not cause 
irritation at the site of injection, but more studies need to be done regarding the cell 
permeability of HPβCD and drug complex formation and how fast the onset of action 
is achieved compared to the dissociation of local anaesthetics as their hydrochloride 
salts. 
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